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ABSTRACT 
A STUDY ON SECONDARY BACTERIAL INFECTIONS IN PATIENTS WITH 
VENOUS LEG ULCER AND THEIR ANTIMICROBIAL SUSCEPTIBILITY 
PATTERN IN A TERTIARY CARE HOSPITAL. 
INTRODUCTION 
Venous  legulcer is the commonest cause of Leg ulcers. It is the most advanced 
manifestation of chronic venous insufficiency (CVI).Venous ulcers are very painful and 
carry a risk of infection. Venous ulcers affect the morale of the people and make them 
withdrawn from the society and work.Wound Care requires a significiant time and 
money.They affect the quality of life and their productivity at work places. 
The  venous ulcer is defined as a full-thickness defect of skin, most frequently in ankle 
region, that fails to heal spontaneously and is sustained by Chronic Venous 
Diseases(CVD) (duplex studies). 
MATERIALS AND METHODS 
This  is a cross sectional study 
Study period : October 2014 to August 2015. 
Study population : 100 patients with venous leg ulcers.  
The two bits of tissue are collected from the venous ulcers under aseptic precautions and 
processed quantitatively. Anaerobes are identified using Anaerobic identification disks. 
Antibiogram was done using Kirby-Bauer disk diffusion method for aerobes. 
  
RESULTS 
Out of 100 ulcers,46% of the ulcers were ulcers with single organism. 45% of the ulcers 
were polymicrobial.Out of 100 Ulcers,48% ulcers were found to be infected.56 pathogens 
were isolated from these ulcers.Staphylococcus aureus was the commonest pathogen to 
be isolated.Methicillin resistant Staphylococcus aureus was isolated from 13% of the 
ulcers.38.4% of MRSA were moderate biofilm producers. Streptococcus pyogenes were 
isolated from 3% of the cases. ESBL producers were 18.3% among the 
Enterobactericeae. 
CONCLUSION 
The quantitative culture of tissue in venous leg ulcers helps to assess the bacterial load in 
the ulcers and aids in treatment modalities. 
KEY WORDS 
Venous leg ulcers,Quantitative culture of tissue, MRSA, Chronic venous insufficiency 
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INTRODUCTION 
Venous ulcer is the commonest cause of Leg ulcers. It is the most advanced 
manifestation of chronic venous insufficiency (CVI).Venous ulcers are very painful 
and carry a risk of infection. Venous ulcers affects the morale of the people and 
makes them withdrawn from the society and work. Wound care requires a 
significant time and money. They affect the quality of life and their productivity at 
work places. 
According to the American Venous Forum (AVF) consensus statement, “The  
venous ulcer is defined as a full-thickness defect of skin, most frequently in ankle 
region, that fails to heal spontaneously and is sustained by Chronic Venous 
Diseases(CVD) (duplex studies)[1]”. 
Venous leg ulcers (VLU) are irregular, shallow and located over bony 
prominences and are usually recurrent. An open ulcer can persist for weeks to years. 
Early diagnosis and management of the primary venous pathology are the crucial 
steps  to prevent  recurrence of a venous ulcer . 
All chronic wounds are colonized by bacteria [2] but Wound infection is 
detrimental to wound healing. 
The constant presence of bacteria in the venous ulcers stimulates the host 
immune defenses leading to the production of inflammatory mediators. Cytotoxic 
enzymes and free oxygen radicals are continuously released as neutrophils keep 
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migrating into the ulcer. Thrombosis and vasoconstrictive metabolites cause wound 
hypoxia, leading to enhanced bacterial proliferation and continued tissue 
damage[3].Evasion of the body’s immune system by bacteria make it difficult to be 
negated by the host defenses. This development of “immune tolerance” can mask 
the infection and may prevent treating the infection. 
Biofilm formation is common in chronic wounds because of the moist 
adherent environment where bacteria aggregate and become embedded in a self-
secreted exopolysaccharide matrix. The presence of such biofilms results in 
inefficient eradication of bacteria by antibiotic treatment and host defense 
mechanisms.[4]It delays wound healing   and favors the emergence of resistant 
bacteria. 
The interpretation of clinical findings and microbiological investigations in 
patients with chronic leg ulcers from colonization to infection can help clinicians 
with the management of ulcers. The quantitative wound culture will help to detect  
bacterial burden.  
This study is done to determine the etiological agents infecting and 
colonizing the venous leg ulcers and their antimicrobial sensitivity pattern. This 
study will be  also useful for distinguishing the patients with infected ulcers from 
colonized one,therefore preventing inadvertent use of antibiotics and restricting the 
use only to the appropriate infected population. 
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AIMS  
1. To determine the bacteriological profile in venous ulcer patients  
2. To categorize the wound based on bacterial burden 
3. To study the resistance pattern of the isolates 
OBJECTIVES 
1. To isolate and identify the bacteria infecting the  patients with venous leg 
ulcers. 
2. To quantify the bacterial burden of the wound . 
3. To determine the antimicrobial susceptibility pattern of the isolated 
organisms and study their resistance pattern in  venous ulcers 
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REVIEW OF LITERATURE 
Venous ulceration is the most common and serious consequence of severe 
chronic venous insufficiency. They are the most common cause of leg ulcers, 
accounting for 60-80% of them. The prevalence of VLUs is between 0.18% and 
1%.Over the age of 65, the prevalence increases to 4%[5].The ulcers which persist 
for more than 6 weeks are defined as  chronic VLUs[6] 
DEFINITIONS 
THE AVF CONSENSUS STATEMENT[1]:  Venous  ulcer   is  defined  as  a  
full-thickness defect of skin, most frequently in ankle region, that fails to heal 
spontaneously and is sustained by CVD (duplex studies). 
THE SCOTTISH GUIDELINE DEFINITION [6]: Chronic venous leg ulcer is 
defined as an open lesion between the knee and the ankle joint that remains 
unhealed for at least four weeks and occurs in the presence of venous disease. 
Studies reviewed in this guideline included patients with venous leg ulcers, 
irrespective of the method of diagnosis of  venous  reflux. 
FRENCH HEALTHCARE SYSTEM GUIDELINES [7]: 
A pure venous ulcer is defined, by professional agreement, as a leg lesion, 
which has not healed within a month (except in cases of recurrent ulcers when a 
diagnosiscan be made in less than a month); with a pathophysiology due to 
ambulatory venous hypertension, which maybe secondary to: reflux in superficial, 
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perforating or deep veins, and/or obstruction of the deep veins, and/or calf muscle 
pump dysfunction; where there is no arterial involvement. 
HISTORY 
The word “Varicose” is derived from Greek, meaning “Grape like”. 
Hippocrates was the first person to appreciate the relationship between calf pump 
dysfunction and venous ulceration .[8] 
In the Susrutha Samhitha, Susrutha had described superficial 
thrombophlebitis and its treatment  by Jalaukavacharan or blood letting using 
leech.[9] 
Aurelius Cornelius Celsus (53 BC to 7 AD) used bandages for the treatment 
of leg ulcers. Galenus (130–200 AD) excised segments of veins controlled between 
ligatures.[9] 
The theory of valvular incompetence as a cause for varicose veins was put 
forward by Hieronymus Fabricius in 1603. Dilatation of vein as a cause for valvular 
incompetence was suggested by Richard Wiseman (1676). He coined the term 
varicose ulcer[9]. 
Interestingly, the management of venous ulcers has not progressed very far 
beyond that advocated by John Hunter over 200 years ago. Hunter said, “The sores 
of poor people are often mended by rest, a horizontal position, fresh provisions, and 
warmth.” 
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John Gay(1868), a London surgeon, described the relationship of venous 
ulceration to ankle perforating veins.He identified the importance of deep vein 
thrombosis (DVT) and the  importance of ankle perforating vein in the genesis of 
leg ulcers. He coined the term “Venous ulcer”[9] 
Sir Benjamin Brodie (1846) described a bedside test for the identification of 
incompetent valves, by the use of constriction and palpation of the limb. Friedrich 
Trendelenburg (1844 – 1924)  refined the method in 1890. 
An important breakthrough was by Paul Gerson Unna (1896). He introduced 
“The Unna Boot”. He incorporated emollient compounds in a dressing that became 
increasingly rigid He was responsible for developing dermatology as an 
independent speciality[10] 
Conrad Jobst (1930), a successful engineer, suffered from  refractory venous 
ulcers. Jobst introduced graduated compression stocking for control of his own 
disease.[9] 
Phlebography was introduced by  Berberich and Hirsch, Sicard and Forestier 
in the 1920s. Dos Santos in 1938 described ascending venography for the diagnosis 
of DVT. by Sigel and Colleagues (1967) introduced the  Doppler for the evaluation 
of venous diseases.   The present gold standard for the assessment of vascular 
disorder is  Duplex ultrasound .It was introduced by Szendro, Nicolaides, Myers, 
Malouf et al. in 1986[9]. 
 
FIGURE 1: ANATOMY OF VENOUS SYSTEM OF LOWER LIMB 
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Several academic forums are actively involved in the study and research on 
venous diseases[9]. They are 
The American Venous Forum (AVF) 1987 
The European Venous Forum 2000 
Two academic societies in India that are active in the field of venous diseases are 
x Vascular Society of India (VSI):  1994  
x Venous Association of India (VAI): established in 2007 to promote research 
and study of venous diseases.  
The society maintains healthy collaboration with other sister organizations 
across the world. 
ANATOMY OF THE VENOUS SYSTEM OF LOWER LIMB[11] 
The lower extremity venous system includes 
1. The superficial, 
2. The Deep, and 
3. The Perforating veins  
The antegrade flow of blood within these veins is ensured by a system of muscular 
venous pumps and bicuspid valves 
The Superficial Veins  
The superficial venous system includes [11] 
The reticular veins  
The great  saphenous vein and their tributaries 
The small saphenous veins 
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The reticular veins 
The reticular veins are a network of veins running  parallel to the skin 
surface and lying between the saphenous fascia and dermis. They drain the lower 
extremity skin and subcutaneous tissue.[11] These veins communicate with either 
saphenous tributaries or the deep veins through perforators. 
THE GREAT SAPHENOUS VEIN (GSV) 
It is the longest vein in the body, situated in the Superficial fascia and is seen 
easily through the skin .The Great saphenous vein is formed on the medial aspect of 
dorsum of foot by the union of dorsal venous arch and digital vein from the medial 
great toe.The main trunk of the great saphenous vein has six valves.It has nine main 
tributaries among which the  posterior arch vein drains a network of medial ankle 
veins and is important in that the posterior tibial perforators join this vein rather 
than the main trunk of the great saphenous vein. 
THE SMALL SAPHENOUS VEIN (SSV) 
The small saphenous vein, formerly known as the short or lesser saphenous 
vein, arises from the dorsal pedal arch and ascends posterolaterally from behind the 
lateral malleolus to terminate in the popliteal vein. The small saphenous vein 
usually has 7 to 10 closely spaced valves.The lateral arch vein , the major tributary 
of the small saphenous vein  communicates with the peroneal vein through the 
lateral calf perforators. The small saphenous vein communicates with the medial 
ankle perforators through several tributaries. 
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THE DEEP VEINS 
The  major  deep  veins  of  the  lower  extremity  follow  the  course  of  the  
associated arteries and, with the exception of the femoral vein, are named 
accordingly.The deep venous system of the calf includes  the tibial, peroneal, soleal 
and gastrocnemial veins. The anterior tibial, posterior tibial and peroneal veins are 
the venae comitantes of the corresponding arteries.The paired veins communicate in 
a plexiform arrangement around the artery. [11]The number of deep venous valves 
increases from cranial to caudal. 
THE PERFORATING VEINS 
There are two types of Perforators. 
1. Direct-Drain into Deep veins 
2. Indirect-Drain into the venous sinuses of calf muscles 
There are about 150 Perforating veins in the lower extremity[12]. 
The direct perforators are localized into five  groups. 
They are 7-9 cms,10-12 cms,18-22  cms,23-27 cms and 28-32 cms proximal 
to the medial malleolus.[11] The indirect perforators are randomly distributed. The 
medial calf perforators are important clinically.   
Perforators are  present in foot, ankle ,below knee ,around the knee. There 
are perforators  of Femoral canal and Inguinal perforators. The foot perforators 
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directly flow towards the superficial veins. All others directly flow to the deep 
system. The major perforators of the medial calf and thigh have one to three valves 
that direct flow from the superficial to the deep veins.[11] 
Venous Sinuses of the Calf Muscle[11] 
These are large thin-walled blood filled spaces located mostly in the soleus 
(1–18 sinuses) and to a less extent in the gastrocnemius muscle. Venous sinuses of 
the soleus muscle drain into the posterior tibial vein through multiple large, short, 
and tortuous soleus veins. Gastrocnemius veins drain the two heads of the muscle 
and empty into the popliteal vein distal to the Saphaneopopliteal junction. These 
sinuses are filled from the superficial veins and the reticular venous plexuses. They 
can hold a large volume of blood and can function as chambers of the peripheral 
heart. 
THE CALF MUSCLE PUMP 
The accumulation of blood in the lower extremity veins while upright is 
limited by the physical properties of the venous wall, the function of the venous 
valves, and theaction of the calf muscle pump.Three muscle pumps are The foot, 
The calf, and The thigh  muscle pumps.[11] 
The action of these valved pumps is dependent on the deep fascia of the 
leg.It constrains the muscles during contraction and allows high pressures to be 
generated within the muscular compartments.With contraction of the calf, pressure 
in the posterior compartment rises to as high as 250 mmHg.The veins are emptied 
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of blood, and resting venous pressure is lowered as the valves prevent retrograde 
flow. The muscular venous sinuses are the principal collecting system of the calf 
muscle pump.The constituents of the Calf muscle pump are Soleus sinuses (one to 
eighteen) and gastrocnemial network .The soleal sinuses communicate with the 
posterior tibial vein in the proximal calf .The gastrocnemial network coalesces to 
form the paired gastrocnemial veins draining into the popliteal vein.[11] 
PATHOPHYSIOLOGY[13] 
PATHOPHYSIOLOGY OF CHRONIC VENOUS INSUFFICIENCY(CVI) 
Blood returns from lower extremities against gravity to Inferior vena cava 
(IVC) through deep and superficial venous system located within muscles and deep 
fascia of legs. The superficial system consists of GSV and SSV located within 
Subcutaneous fat. Valves present within all these systems  prevent retrograde flow 
of blood .A portion of blood from superficial systems is  directed to deep system 
through communicating perforators. While standing, about 22% of total blood 
volume is localized in lower extremities. 
Thegeneral pathophysiologyof chronic venous insufficiency are 
1. Sustained central outflow obstruction following the thrombosis of central 
portions of venous tree 
2. Congenital abnormality 
3.  Reflux in the deep venous thrombosis or a pressure volume overload 
associated with varicose veins 
4. Congenital autosomal dominant absence of all venous valves (rare) 
 
 
 
12 
 
PATHOPHYSIOLOGY OF VENOUS ULCER[13] 
The most common site of occurrence is the retromalleolar fossa located 
between the medial malleolus and Achilles tendon.Ulcers can occur at any site 
where venous hypertension is especially pronounced due to local circumstances.ie 
proximity to incompetent perforators and on lateral or medial dorsum of foot. 
Venous incompetence and venous hypertension are thought to be the primary 
mechanisms for ulcer formation. 
 Factors that  lead to venous incompetence are  
1. Immobility 
2. Ineffective pumping of the calf muscle 
3. Venous valve dysfunction from trauma, congenital absence, venous 
thrombosis, or phlebitis [13]. 
 
Chronic venous stasis 
 
Pooling of blood in venous circulatory system 
 
Capillary  Damage and activation of inflammatory process 
 
 
Venous Ulcer 
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Leukocyte activation, endothelial damage, platelet aggregation, and 
intracellular edema contribute to venous ulcer development and impaired wound 
healing. 
Chronic venous disease is accompanied by infiltration of circulating 
leukocytes  in the microcirculation that reduces local capillary perfusion .This 
enhances formation of  free radical oxygen, delivery of proteolytic enzymes, 
synthesis and release of  inflammatory molecules such as leukotrienes, 
prostaglandin, bradykinin and cytokines.This leads to  tissue degradation. Vascular 
endothelial growth factor (VEGF), by definition, is a potent angiogenic factor which 
enhances endothelial permeability. Both VEGF expression and its receptor 
expression (Flk-1/KDR) are upregulated during the inflammatory reaction. Venous  
ulcer exudates  inhibit the growth of human endothelial cells[13].  
Transforming growth factor beta(TGF) is another cytokine whose expression 
is upregulated in patients with venous ulcers.It is related to tissue remodeling by 
stimulating the formation of the granulation tissue, proliferation of  fibroblasts, and 
synthesis of collagen fibers. An important link between inflammation and skin 
changes  may  be  by  way  of  Ca/Zn-dependent  endoproteinases   (Matrix   
Metalloproteinases (MMPs)) and serine proteinases.[13] 
Chronic Venous ulcers are characterized by excessive proteolytic activity, 
which degrades extracellular matrix and growth factors and their receptors. There is 
an increase of neutrophil elastase and lactoferrin from activated neutrophils in 
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patients under transient conditions of venous hypertension and with chronic venous 
insufficiency. Neutrophils and macrophages also release several MMPs. Venous leg 
ulcers have elevated expression of Extracellular MMP inducer (EMMPRIN; 
CD147) which increases the MMP expression [13]. 
Another factor that contributes to the lack of proper restructuring in venous 
ulcer fibroblasts demonstrates decreased proliferative responses to growth factor 
stimulation. Venous diseases have recurrent inflammation without definitive 
resolution. The inflammatory cascade remains active. Telangiectases develop into 
varicose veins, skin edema, pigmentation, venous eczema, and into active venous 
ulcers. Treatment needs to interfere with the inflammatory cascade that causes 
tissue damage but cannot be targeted against the tissue repair mechanism. 
ROLE OF LYMPHATICS IN VENOUR ULCERS[14] 
Lymphatic function is reduced in venous ulcer patients. In severe Chronic 
venous insufficiency and venous ulcers, Lymphatics become compromised. 
Oedema and skin changes occur. In severe CVI, lipodermatosclerosis may occur 
with ulceration.There is complete absence of lymphatics in ulcer bed and there is 
marked decrease of lymphatics surrounding the ulcer. The presence of edema 
complicates the management of CVI and particularly venous ulceration leading to 
poor wound healing. 
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PREDISPOSING FACTORS 
The following factors account for chronic venous insufficiency and venous 
ulcers.[15] 
1. Older age 
2. Obesity 
3. Varicose veins 
4.  Heart failure  
5. Diabetes 
6. Rheumatoid arthritis 
7.  Nephrosis 
8.  History of venous thrombosis 
9.  Multiple pregnancies 
10.  Hypertension 
11. Life style and Family History 
12. Occupation 
 
About 5% of patients will develop leg ulcers following a clinically apparent 
DVT . 
Congenital vein abnormalities-, Klippel-Trenauay-Parkes-Webber 
syndrome[16]is present at birth  .Older children have active to healed venous ulcer. 
Rheumatoid arthritis, systemic vasculitis adversely affect the prognosis and the 
outcome of the treatment[17] 
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CLINICAL FEATURES 
Patients with ulcer due to Chronic  venous insufficiency  complain of lower 
extremity pain and swelling of the leg usually beginning near the medial malleolus 
or gaiter region. CVI causes circulatory dysfunction on the macro- and 
microvascular level leading to a variety of clinical manifestations like  lower 
extremity edema due to  fluid accumulation  in the dependent lower leg, pain, 
dilated veins, and skin changes. 
Symptoms are worse at the end of the day, exacerbated when the leg is 
dependent and relieved by leg elevation in patients with the history of recurrent 
cellulitis ,DVT or previous superficial venous surgery.The prominent clinical 
features that indicate infection include 
Fever,  
Increased pain, 
 Increased swelling , 
Discharge from ulcer, 
Foul smell   
The Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification was 
developed to standardize the classification of patients with CVI. It was introduced 
in 1994 and revised in 2004.[1]according to AVF’s recommendations,all Venous leg 
ulcers are evaluated with the CEAP score. 
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Anatomic classification is based on the involvement of the deep, superficial, 
or perforating veins while the pathophysiological classification  describes the 
underlying mechanism of  CVI as obstruction, valvular incompetence, or a 
combination of both conditions. 
Clinical classification  of  CVI[1] 
C0: no visible or palpable signs of venous disease 
C1: telangiectasies or reticular veins 
C2: varicose veins 
C3: edema 
C4a: pigmentation or eczema 
C4b: lipodermatosclerosis or atrophie blanche 
C5: healed venous ulcer 
C6: active venous ulcer 
Etiologic classification 
Ec: congenital 
Ep: primary 
Es: secondary (post-thrombotic) 
En: no venous cause identified 
Anatomic classification 
As: superficial veins 
Ap: perforator veins 
Ad: deep veins 
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Pathophysiologic classification 
Pr: reflux 
Po: obstruction 
Pr,o: reflux and obstruction 
Pn: no venous pathophysiology  identifiable 
Venous-Severity-Scoring[1] 
The venous severity score (VSS) provides a more detailed assessment of  
CVI  by assigning a numeric score to three components: clinical severity, anatomic 
segment, and disability[10]. VSS provide a more accurate tool for assessing a 
patient’s response to treatment. It was designed to complement, not to replace 
CEAP. 
In 2000 the AVF developed the three-part Venous Severity Score:  
1. Venous Clinical Severity Score (VCSS) –revised in 2010,  
2. Venous Segmental Disease Score (VSDS), and  
3. Venous Disability Score (VDS) - a modification of the original CEAP 
disability score. 
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DIAGNOSIS 
HISTORY AND CLINICAL EXAMINATION[1]: 
Clinical history :Duration,recurrence,pain,trauma, and other co morbid 
factors are  considered. Any clinical symptoms of infection,odour are also taken 
into consideration. 
Physical examination of leg ulcer are evaluated. Examination of both legs are 
done.palpation of peripheral pulses, edema if present whether it is pitting or 
nonpitting type are done. 
Signs of venous hypertension such as varicose veins, hemosiderin 
pigmentation, varicose eczema, atrophie blanche (Healed venous ulcer)  and 
lipodermatosclerosis are noted.[17] 
Range of movements for knee ,ankle and Hip are also determined. 
Clinical assessment of ulcer includes the 
a. The site of the ulcer- Locationof the ulcer: Anterior to medial malleolus, 
pretibial area or lower third of leg (gaiter region) gives clue to the underlying 
cause of ulcer. 
b. Size and  depth, 
c. The edge and margins,  
d. Thefloor,and base, 
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e. Condition of the surrounding skin.  
f. Ankle/brachial pressure index (ABPI): It is an objective evidence to 
substantiate the presence or absence of significant peripheral arterial 
diseases. It is the ratio of the ankle to brachial systolic pressure It is  
measured either using a sphygmomanometer or  hand held Doppler 
device.ABPI 0.8 -1.2 indicates good arterial supply and these patients can be 
given compression therapy safely.[5] 
VASCULAR ASSESSMENT[1] 
Doppler measurement of ankle/brachial pressure index- To indicate any 
arterial insufficiency 
Duplex ultrasound-This investigation is done to reveal any obstruction in 
veins and arteries.Blood flow through Valves, superficial and deep veins  can be 
visualized directly. 
Photoplethysmography-measures the venous refill time. Refill time is 
abnormally increased in patients with venous diseases (<25 seconds).It also 
determines the efficiency of calf muscle Pump.[18] 
Pulse oximetry-It measures the red and infrared light  absorption of  
oxygenated and deoxygenated blood .Oxygenated blood absorbs more red light and 
deoxygenated blood more infrared light.  Pulse oximetry is considered to support 
the diagnosis of venous ulcer. 
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Toe brachial pressure index (TBPI)-Non invasive test to measure the arterial 
perfusion in toes. It is used in diabetics and renal disease. 
MICROBIOLOGY 
Skin is the mechanical barrior   to microorganisms .The normal flora and pH 
controls the invasion of the skin by microorganism. When it is breached the wound 
gets contaminated by normal flora and body fluids .Venous ulcer are colonized by 
aerobic and anaerobic flora.The effect of bacterial burden  is called as  bioburden. 
This initiates proinflammatory cytokines like interleukin -1,tumour necrosis factor-
Į,MMP-2 ,MMP-8.[19] 
All chronic ulcers contain some degree of bioburden. Some wounds are 
infected.Recognizing the range of bioburden in the wounds provides a framework to 
assess the significance and  identify the treatment modalities. The continuum of 
bioburden are[19] [20] 
1. Contamination-Presence of nonreplicating microorganisms on the wound 
surface.Microorganisms may be endogenous or exogenous.Most common 
contaminants are Staphylococcus aureus, Cornyebacterium spp other than 
Cornyebacterium diptheriae, Coagulase–Negative Staphylococcus, 
Escherichia coli, Klebsiella spp, Proteus spp and Anaerobic organisms such 
as Prevotella, Bacteroides spp, Peptostreptococcus spp. 
2. Colonization-Microorganisms adhere to the wound’s Surface and 
replicate.Colonization does not impair wound healing.Inappropriate use of 
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antibiotics during this phase contributes to thegrowth of  antibiotic resistant 
organisms. 
3. Critical colonization-The skin cell proliferation and tissue repair areaffected 
by the bacterial level in the wound. This leads to nonhealing  wounds.[21] 
4. Biofilm –It is a complex structure of microorganism embedded in an 
extracellular matrix of polysaccharide.70% of chronic wounds form biofilm. 
Staphylococcus aureus and Pseudomonas aeruginosa[22] are the commonest 
organism causing chronic biofilm. 
5. Infection-It occurs when microorganisms on the wound surface penetrate 
into wound tissue . A local or systemic response indicates an infection. 
The bacteria on the ulcers cause deterioration of  wound healing. The 
bacterial population present within venous leg ulcer (VLU) with severe infection are 
methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, 
vancomycin resistant Enterococcus, Gram-negative bacteria including, 
Pseudomonas species, Escherichia coli, Acinetobacter species,                     
Klebsiella pneumoniae and other organisms. The number of species present in the 
ulcer, rather than one particular bacterial species, correlates positively with 
impaired healing[23] 
Diagnosis of wound infection is based primarily on clinical assessment and 
microbiological diagnosis. Wound culture is performed primarily to identify the 
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specific aerobic and anaerobic organisms present and their antimicrobial 
susceptibility patterns.  
Criteria for colonization and infection is [21] [19] 
Critical colonization(NERDS) Deep tissue infection(STONEES) 
N-Nonhealing of the wound  S-Size of ulcer  larger 
E-Exudative wound T-temperature increased 
R-Red  and bleeding O-Osteomyelitis (Probes to or 
exposed bone 
D-debris N-New area of breakdown 
S-Smell from the wound E-Erythema/Edema 
 E-Exudate 
 S-Smell 
 
Quantification of  the organisms wound is done to assess the levels of  
bioburden. A quantitative tissue biopsy is the gold standard.                    
Bacterial count of  106Colony  forming  units  (CFU)  per  gram  tissue  is  taken  as  
gold standard for infection in venous leg ulcers.[17] 
Different types of wound culture done are 
CULTURE OF TISSUE 
A deep-tissue or punch biopsy for a quantitative culture (which determines 
the colony counts per gram of tissue) is the gold standard for identifying wound 
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bioburden and diagnosing clinical infection .After initial debridement and cleaning 
of superficial debris with normal saline solution,a deep-tissue biopsy is taken.This is 
the most useful way to detect invasive organisms.[24]Semiquantitative  analysis can 
also be done. 
CULTURE OF SWAB 
The commonest technique used for evaluating wound infection is the surface 
swab culture. Levine technique is the best technique for swab culture [25].Here the 
wound is cleansed of surface exudates with moist saline gauze.A sterile culture 
swab is then pressed and rotated over an area of 1cm2 of the wound .This is done to 
bring the wound fluid (discharge) and bacteria to the surface.It can be analysed  
qualitatively and Semiquantitatively. Alginate tipped swab is used for quantitative 
analysis. 
Another variant of this technique is the Z –stroke technique.The surface is 
swabbed in a Z shape[25] .This is less precise than the Levine’s technique. 
Surface swabs do not adequately reflect the invasive bacterial organisms 
They lack the high sensitivity that wound biopsy achieves.  
There is lot of debate and controversy regarding the type of sample, sampling 
techniques and relevance of wound cleaning before sampling[26].Many research 
works have been done comparing the swab to tissue culture in chronic wounds. 
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NEEDLE ASPIRATES[26] 
When large volume of pus is present, aspiration can be done along the 
wound margin ,after cleaning the wound.This is a useful method. 
TRANSPORT OF SPECIMEN[26] 
Prompt  delivery  of  the  specimen  to  the  laboratory  is  important  for  the  
viability of the specimen. Specimen for anaerobic study should be transported in 
prereduced nonnutritive transport medium Tissue samples and aspirates are 
considered  to  be  preferable  to  swabs  as  they  retain  the  environment  for  the  
microbial viability. 
DIRECT MICROSCOPY[26] 
Gram staining of known volume of tissue biopsy specimen homogenate is 
used to estimate the microbial load of an ulcer. It is a rapid method to facilitate 
identification of Causative organisms in a clean wound .Its value in chronic wound 
is interpreted with the presence of leucocytes. 
ANALYSIS OF WOUND SPECIMEN 
Clinical information regarding the nature of specimen, position of the venous 
ulcer wound, clinical signs of infection,associated comorbid condition ,malodour 
and antimicrobial therapy will help the microbiologist in the processing  and 
analyzing  the specimen. 
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ANAEROBIC CULTURE 
Anaerobes are commonly isolated from venous ulcers. Quantitative culture  
for anaerobic organisms is problematic and less meaningful.  They are secondary 
invaders and tend to live in synergy with other organisms in culture.[27][28] 
ANTIBIOTIC RESISTANCE AMONG BACTERIA IN VENOUS ULCERS 
Bacterial resistance is becoming increasingly common in VLU infection. 
Risk factors  for development  resistance pattern include previous antibiotic therapy 
and its duration, increased frequency and duration  of hospitalization.[29]The patients 
with MRSA can serve as a reservoir for cross contamination through aerosol spread 
and through health care personnel who are involved in changing the 
dressing[30]There is increase in true community-acquired MRSA (CA-MRSA) in the 
long standing venous ulcers. Pseudomonas aeuginosa have intrinisic and acquired 
antibiotic resistance making it difficult to treat. 
The Quorum sensing molecules are associated with biofilm formation and 
the regulation of virulence factors[31].Staphylococcus aureus and           
Pseudomonas aeruginosa are the commonest organisms to form  a biofilm. The 
moist surface of ulcers is favourable for the formation of biofilms.Biofilms confer 
greater resistance to amtimicrobials and make them less susceptibile to host 
response. 
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ANTIMICROBIAL TREATMENT OF VENOUS ULCERS 
Systemic antibiotics are indicated only when there is a clinical signs of 
infection .No routine use of antibiotics are advocated. The guidelines do not 
advocate the use of topical antibiotics .The topical use of antibiotics have led to 
resistant organisms.[30] There are also concerns regarding the toxicity and 
sensitization of the tissue with the use of topical antibiotics. The wounds that are 
heavily colonized and present with local signs of infection  may be treated with 
topical antibiotics.[32]Short course of metronidazole gel can be given  for the 
odoriferous ulcer.[30] 
TREATMENT 
A. Compression therapy 
The compression therapy has been a fundamental treatment component for 
Venous leg ulcers.[1] 
Compression therapy (CT) is defined as the direct application of external 
pressure to the limb with the idea of improving the signs and symptoms of chronic 
venous insufficiency.Methods of compression therapy are [33] 
1.  Compressive bandages – multilayer bandaging-effective  treatment 
available 
2.  Compression stockings 
3.  Intermittent pneumatic compression ( IPC) 
4.  Unna ’s boots and velcro– band devices( legging orthosis) 
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B.  Wound care[17] 
a.  Regular cleaning and debridement  
b.  Ulcer dressings: It is of three categories: Passive (nonocclusive),                                                                 
Interactive (semiocclusive and occlusive types),  Active (biological 
types) 
The passive dressings ( nonocclusive dressings ) protect the wound from 
trauma and potential infection. An example of nonocclusive dressing is dry 
gauzewith pad and bandage.  
The interactive types of dressings maintain a moist warm wound 
environmentand help to control the amount and composition of wound exudate. 
They may be semiocclusive or occlusive type.  
The common types of semi occlusive/occlusive dressings include 
hydrocolloids, hydrogels, films, foam, and calcium  alginates. The active or 
biologicdressings may be living human dermal equivalent (LHDE), platelet 
products – autologous or recombinant and growth factors (epidermal growth factor; 
GMCSF, etc.). 
There is no ideal dressing material for venous ulcers. The saline wet to dry 
gauze dressing is a simple and popular form 
C. Management of pain 
Venous ulcers are generally considered to be painless unless complicated by 
infection. Pain is managed by compression treatment and antimicrobial therapy. 
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D.  Skin grafting for venous ulcers[17]. 
Split-thickness skin grafting is done for  large ulcers requiring extendedtime 
to heal. 
E. MEDICATIONS 
Pentoxifilline ,Vitamin A and E,Calcium channel blockers,Aspirin and 
corticosteroids whenever necessary  
F. SURGERY 
Surgical correction of the underlying cause of chronic venous insufficiency 
is considered whenever possible. 
G. PATIENT EDUCATION[34] 
x Elevation of foot for at least  30 minutes a day. 
x Avoidance of  smoking 
x Reduction of Overweight 
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MATERIALS AND METHODS 
This study on secondary bacterial infections  in venous  leg ulcers patients  
and their antimicrobial susceptibility pattern was carried out in the Institute of 
Microbiology, Madras Medical College ,Chennai 
Study design & period 
Cross sectional study. From October 2014 to August 2015 
Study population 
A total number of 100 patients attending the department of department of 
Vascular surgery, General surgery and Plastic Surgery, Rajiv Gandhi Government 
General Hospital, Chennai were included for the study.  
Ethical clearance 
Prior approval was obtained from the Institutional Ethics Committee. 
Informed consent was obtained from  the in-patients and out patients who satisfied 
the inclusion criteria.  
Inclusion criteria 
x Patients older than 18 years.  
x IP/OP Patients with Venous leg ulcers  with  one or more of the following 
clinical signs of infections 
Fever 
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Increased pain 
Discharge 
Malodour 
Increased oedema 
Exclusion criteria:  
x Patients with arterial ulcers,Filarial ulcers  
x Patients with neurotrophic ulcers- Diabetic ulcer, Leprotic ulcer 
x Patients with venous leg ulcers having no clinical signs of infection.  
 
COLLECTION OF DATA 
Data were collected from patients who satisfied the inclusion 
criteria.Demographic details like name, age, sex, address, date of admission, clinical 
data like presenting complaints, personal history, past medical history, 
immunocompromised status, physical examination findings and details of clinical 
diagnosis and investigations were collected.  
METHODLOGY FOLLOWED IN THE STUDY 
As the Quantitative culture of the  tissue  is the Gold standard,This procedure 
was followed in this study. 
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SAMPLE COLLECTION AND TRANSPORT  
Samples collected 
Tissue: The ulcer  was cleaned with normal saline.Under aseptic precautions 
two tissue bits were collected from the ulcer bed with a sterile scalpel.One tissue bit 
was transferred into a sterile universal container and another bit into Robertson’s 
cooked meat broth and transported to the laboratory. 
PROCESSING OF SPECIMEN 
TISSUE[35] 
The tissue was weighed in a preweighed sterile petridish on an analytical 
balance. Tissue was homogenized with a sterile scalpel in the petridish and 
transferred to a sterile test tube containing 5 ml of 0.85% normal saline and vortex 
mixed. 
DIRECT GRAM STAIN[26] 
0.2 ml of tissue homogenate was applied on a clean glass slide and was 
spread as a thin smear. It was allowed to air dry for 15 minutes and heat fixed. 
Gram staining was done andthe smear was examined with 100x oil immersion 
objective. 
 The presence of a single organism per field was regarded as equivalent of 
the 105 bacteria per gram of tissue. Gram stain morphology and presence of any pus 
cells were documented. 
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Processing of tissue for quantitative culture[35] 
The tissue homogenised was transferred into a sterile test tube containing 5 
ml of 0.85%normal saline and was vortex mixed .It was plated onto MacConkey 
Agar and serially diluted 10 folds before plating onto Blood agar. The plates were 
incubated at 37°C aerobically. 
The  number  of  Colony  Forming  Units  (CFU)  per  gram  of  tissue  was  
calculated by applying the following formula: 
 Number of CFUs counted x Reciprocal of volume of homogenate inoculated 
(10Ø¹ or 10Ø²) x 2 (volume of diluents used for tissue homogenization) divided by 
the weight of tissue in grams. 
Interpretation: ----------- CFU/ gram tissue 
Anaerobic culture  
For anaerobic culture, the tissuewas inoculated directly into Robertson 
cooked meat broth(RCM) and transported to the laboratory. 
Processing of specimen: [36]  
Tissue bits were inoculated onto freshly prepared e anaerobic blood agar 
plates(Appendix-II) and placed in anaerobic jar with media facing upwards. 
AnaeroGas (HiMedia)was placed inside the McIntosh Fildes anaerobic  jar and the 
lid of the jar closed immediately .Lid was sealed with petroleum jelly and kept for 
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incubation for  48 hours at 37ºC.A blood agar plate inoculated with ATCC 
Pseudomonas aeruginosa-27853 was placed in the jar which served as a control to 
check anaerobic process.  
After 48-72 hours, all primary plates were examined .Identification of 
anaerobic bacteria was one by Colony morphology, Gram’s staining and by using   
antibiotic identification disks.The culture was  subcultured onto  anaerobic blood 
agar plates with following antibiotic identification disks 
x Kanamycin-1 mg 
x Colistin-10  µg 
x Vancomycin-5µg 
x Nitrate  disk for Gram negative organism and Nitrate disk and  Sodium 
Polyanetholsulfonate  (SPS) disk were added for Gram positive 
organismsand incubated anaerobically in McIntosh Fildes jar for 48-72  
hours. 
Colonies were also subcultured onto chocolate agar plate and incubated in 
5% carbon dioxide in a candle jar for aerotolerance at 37ºC.Since no growth was 
observed after 48 hours,the isolate was considered as obligate anaerobe. 
IDENTIFICATIONOF ISOLATES 
 All the bacterial isolates obtained from the samples were identified by 
standard bacteriological techniques 
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 Beta haemolytic colonies and golden yellow pigment on blood agar,      
Gram positive cocci in clusters on Gram stain,  positive catalase test,  positive slide 
coagulase test,  positive tube coagulase test, positive urease test, fermentation of 
mannitol, positive Methyl Red (MR) test, positive Voges Proskauer (VP) test, and 
production of phosphatase were identified as Staphylococcus aureus[38] 
 Staphylococcus epidermidis was identified by, white opaque colonies on 
blood agar, Gram positive cocci in clusters on Gram stain, positive catalase test, 
negative slide coagulase test, negative tube coagulase test, production of 
phosphatase, sensitive to Novobiocin, resistant to Polymyxin B and negative 
mannitol fermentation[38] 
Micrococci is identified by ,lactose fermenting colonies on MacConkey agar, 
Gram positive cocci in tetrads, positive catalase test, modified oxidase test 
positive.[38] 
 Streptococcus pyogenes was identified by, beta hemolysis on blood agar, 
Gram positive cocci in pairs and short chains ,Gram stain, negative catalase test, 
sensitivity to bacitracin 0 .04 units ,negative bile esculin test.[39] 
 Enterococcus faecalis was identified by, non-haemolytic tiny colonies on 
blood agar, Gram positive cocci in pairs and short chains on Gram stain,  negative 
catalase test, positive bile esculin test, positive arginine dihydrolase test, 
fermentation of mannitol, non-fermentation of arabinose, heat tolerance (surviving 
at 60oC for 30 min)[39]. 
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Diphtheroids were identified by white opaque colonies on 5% Blood 
agar,Gram positive bacilli on Gram stain,non motile detected by hanging drop 
method,positive catalase test,negative oxidase test, and with Urease test, Nitrate 
reduction test, Fermentation of glucose, Esculin hydrolysis, Arginine dihydrolase 
test, VP test and fermentation of sugars.[43] 
Escherichia coli was identified by, lactose fermenting colonies on 
MacConkey agar, Gram negative bacilli on Gram stain, motile bacilli detected by 
hanging drop method, positive catalase test, negative oxidase test, positive nitrate 
reduction test, positive indole test, positive MR test, negative VP test, negative 
citrate utilization test, acid butt and acid slant with gas on TSI, negative urease test 
and fermentation of sugars with acid and gas.[40] 
Proteus vulgaris was identified by ,non lactose fermenting colonies on 
MacConkey agar, Grey white colonies with swarming in Blood agar,Gram negative 
bacilli on Gram stain,motile bacilli detected by hanging drop method, positive 
catalase test, negative oxidase test, positive nitrate reduction test, positive indole 
test, positive  MR  test, negative VP test, positive citrate test, acid butt and alkaline 
slant with H2S production on TSI,Positive urease test ,positive phenylalanine 
deaminase test and fermentation of sugars.[40] 
Proteus mirabilis was identified by ,non lactose fermenting colonies on 
MacConkey agar, Grey white colonies with swarming in Blood agar,Gram negative 
bacilli on Gram stain,motile bacilli detected by hanging drop method,Positive 
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catalase test, negative oxidase test, positive nitrate reduction test, negative indole 
test, positive MR test, negative VP test, positive citrate test, acid butt and alkaline 
slant with H2S production, on TSI,Positive urease test ,positive phenylalanine 
deaminase test and fermentation of sugars,positiveOrnithine decarboxylation[40] 
Klebsiella oxytoca was identified by lactose fermenting mucoid colonies on 
MacConkey agar, short Gram negative bacilli on Gram stain, non-motile bacilli 
detected by hanging drop method, positive catalase test, negative oxidase test, 
positive nitrate reduction test, positive indole test, negative MR test, positive VP 
test, positive citrate utilization test, acid butt and acid slant with gas on TSI, positive 
urease test and fermentation of sugars with acid and gas.[40] 
Klebsiella pneumonia was identified by lactose fermenting mucoid colonies 
on MacConkey agar, short Gram negative bacilli on Gram stain, non-motile bacilli 
detected by hanging drop method, positive catalase test, negative oxidase test, 
positive nitrate reduction test, negative indole test, negative MR test, positive VP 
test, positive citrate utilization test, acid butt and acid slant with gas on TSI, positive 
urease test and fermentation of sugars with acid and gas[40]. 
Pseudomonas aeruginosa was identified by, non-lactose fermenting colonies 
on  MacConkey agar, production of bluish green pigment on nutrient agar, slender 
Gram negative bacilli on Gram stain, motile bacilli detected by hanging drop 
method, positive catalase test, positive oxidase test, oxidative reaction in Hugh & 
Leifson Oxidative and fermentative medium, positive nitrate reduction test, negative 
 
 
 
38 
 
MR test, negative VP test, alkaline butt and alkaline slant with gas on TSI, positive 
arginine dihydrolase test and negative lysine decarboxylation[41] 
 Acinetobacter baumannii was identified by, non-lactose fermenting colonies 
on MacConkey agar, Gram negative coccobacilli on Gram stain, nonmotile bacilli 
detected by hanging drop method, positive catalase test,negative oxidase test, 
oxidative reaction in Hugh & Leifson O/F medium,10% OF lactose 
positive,negative nitrate reduction test, negative MR test, negative VP test, alkaline 
butt and alkaline slant  on TSI, Growth at 42°C.[42] 
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IDENTIFICATION OF ANAEROBES[36] 
Interpretation of antibiotic identification disk method for anaerobic identification 
Organism Gram Stain Vancomycin 
5µg 
Kanamycin 
1 MG 
Colistin 
10 
Nitrate SP
S 
Catal
ase 
Peptostrepto
coccus 
anaerobicus 
Gram positive 
cocci 
Or 
Coccobacilli 
S R R - S - 
Bactroides 
fragilis 
Gram 
negative 
bacilli 
R R R + - - 
 
ANTI MICROBIAL SUSCEPTIBILITY TESTING[44][45] 
All aerobic Bacterial isolates were tested for antimicrobial susceptibility 
pattern using Kirby –Bauer Disc diffusion Method. 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN TESTING BY KIRBY-
BAUER DISC DIFFUSION METHOD 
Inoculum Preparation and procedure 
3-5 similar colonies  from 24 hour culture was transferred to a sterile testtube 
containing 3 ml of peptone water with the help of  sterile bacteriological loop. 
The same was emulsified and turbidity matched with 0.5 McFarlands 
standards. 
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1. By using Sterile cotton swab, The suspension was evenly  streaked over 
cation adjusted Mueller Hilton agar in three directions approximately at 60° 
to evenly distribute the inoculum. 
2. Antibiotic disks (HiMedia) were placed on the agar plate  after allowing the 
plates to dry for 3-5 minutes.(Appendix) with a sterile forceps. 
The petridishes were incubated overnight at37°C aerobically for 24 
hours.The diameter of Zone of inhibition were read with the ruled template. 
Interpretation was done according to the CLSI guidelines.(Appendix-III) 
For diphtheroids, A panel of  three drugs were tested and interpreted 
according to the British society of antibiotic chemotherapy (BSAC) (Appendix –III) 
Quality control tests were done every week with following ATCC strains to 
test the efficacy of media and drugs. 
ATCC control strains:  
x Staphylococcus aureus–ATCC 25923  
x Escherichia coli-ATCC 25922  
x Pseudomonas aeruginosa-ATCC 27853  
x Klebsiella pneumoniae(ESBL)-ATCC 700603  
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Identification of Methicillin resistant staphylococcus aureus[45] 
Screening test 
3-5 colonies from overnight culture was transferred to 2 ml peptone water 
and emulsified .The turbidity was matched with 0.5 McFarlands standard. 
Lawn culture was made with the same on Muller Hilton agar plate and 
Incubated overnight at 33-35°C.Cefoxitin 30µg disk was placed on the agar plates. 
The Zone of Inhibition was interpreted according to CLSI guidelines. 
A similar lawn culture of ATCC Staphylococcus aureus 25923 was put up as 
Quality control strain. 
Interpretation of Zone of Inhibition  
Organism 
Methicillin 
Sensitive 
Methicillin 
Resistant 
Staphylococcus aureus and 
Staphylococcus lugdunensis 
22 mm 21mm 
Coagulase negative 
staphylococcus  
25 mm 24 mm 
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DETERMINATION OF MINIMUM INHIBITORY CONCENTRATION 
(MIC) BY MACROBROTH DILUTION METHOD FOR VANCOMYCIN 
RESISTANCE[46][47] 
Requirements 
1. Culture media: Cation  adjusted Mueller Hilton (MH )  broth (pH7.2-7.4) 
Preparation of antibiotic stock solution: 
Vancomycin used for preparing the stock solution was obtained from HiMedia 
Weight of antibiotic for preparation of stock solution was calculated by the formula  
                       1000               
W  =   ------------------------ x V x C 
     P 
 
P = Potency of the antibiotic in relation to the base (For Vancomycin, P=950/1000) 
V= Volume of the stock solution to be prepared 
C=Final concentration of antibiotic solution (1024 µg/ml) 
W= weight of the antibiotic to be dissolved in the volume V 
10.8 mgs of the drug is added to 10 ml of the distilled water for the final 
concentration 1024 µg/ml. 
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PREPARATIONOFANTIBIOTIC DILUTION 
1. Two rows of 14 sterile test tubes were arranged in a rack.First row for Test 
organism and second for ATCC control. 
2.    1  ml  of  MH  broth  was  transferred  to  all  the  tubes  in  the  rack  using  
micropipette. 
3.  1 ml of Stock solution was transferred to the first test tube in each row and 
mixed well. 
4. 1 ml from the first test tube was transferred to the second tube and serially 
diluted till 14th tube. 
5. One tube containing only antibiotic solution was kept for drug control. 
6. Inoculum Preparation: To 9.9 ml of MH broth 0.1 ml of 0.5 McFarland 
turbidity organism was added  and mixed well. From the above prepared 
inoculum 1 ml was transferred to each tube kept for test organism.One tube 
containing only the test inoculum was kept as controlSame procedure was 
repeated for ATCC control strain 
7.  The test tubes were incubated at 37°C overnight. 
 
INTERPRETATION[45]: 
MIC of ATCC Staphylococcus aureus 25923 and the test organism was 
observed 
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The lowest concentration of the antibiotic which showed clearing was 
considered  as  the  MIC  for  the  ATCC  strain  and  for  the  test  organism  was  
interpreted as follows according to CLSI guidelines 
MIC of Vancomycin 
 2 µg/ml- Susceptible 
4-8  µg/ml-Intermediate 
 16  µg/ml-Resistant 
ANTIMICROBIAL SENSITIVITY TO CLINDAMYCIN[45] 
INDUCIBLE D TEST 
The antimicrobial sensitivity to Clindamycin for Gram positive cocci was 
done as follows 
A lawn culture of the isolate was done after matching the inoculum with    
0.5 McFarlands Standard.  Erythromycin 15µg disk and Clindamycin 2µg disk were 
placed 15 mm apart and incubated at 37ºC for 18 hours. 
Interpretation 
Hazy growth within the zone of inhibition-Clindamycin resistant 
Flattening of zone of inhibition adjacent to the erythromycin disk was 
considered as inducible Clindamycin resistance 
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The isolates were reported as sensitive to Clindamycin only when there was 
no inducible resistance to Clindamycin 
DETECTION OF BIOFILM FORMATION BY METHICILLIN REISTANT 
STAPHYLOCOCCUS AUREUS BY TISSUE MICROTITRE PLATE[48][49][50] 
1.  1-2 colonies  from fresh agar plate  of test organism were inoculated 
in 3 ml of Trypticase soy broth (TSB) with 1% glucose and incubated 
for 24 hours at 37°C . 
2. The  inoculum for the biofilm detection was diluted with fresh  
Trypticase  soy broth so that final concentration corresponded to 1 in 
100 dilution 
3. 0.2 ml of the diluted inoculum was transferred to the individual wells 
of sterile Polystyrene ,96 well-Flat bottom tissue culture plates 
(TARSON) 
4. Controls were set up in individual well- Blank well, crystal violet, 
sterile Trypticase  soy broth, fixative. 
5.  ATCC Pseudomonas aeruginosa-ATCC 27853 and ATCC 
Staphylococcus aureus-ATCC 25923 were set up as the  Positive 
control and negative control for  biofilm producer respectively 
6. The test  was done in triplicates and the plates were incubated at 37°C 
for 24 hours at 37°C. 
7. After incubation, the contents of the well were removed by gentle 
tapping. 
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8. The wells were washed with 0.2 ml of Phosphate buffer solution 
(PBS) for four times. This was done to remove the planktonic 
bacteria. 
9. The biofilm thus formed was fixed to the plate with 2 % sodium 
acetate and stained with 250 µl of 0.1 % crystal violet  and incubated 
at room temperature for 20 minutes. 
10. Excess stain was rinsed off by washing with 250 µl of deionised water 
for four times. 
11. 200 µl of 95%ethanol was added to solubilize the Crystal violet and to 
extract the violet colour to quantify it. 
12. Optical density of adherent bacteria were determined with a Micro 
ELISA auto reader at wavelength of 570 nm (OD 570nm). 
13. The OD valves were calculated. 
 ODC value was calculated using the formula 
 ODC (Optical density cut off value)  =  Average  OD of Negative 
control + 3 x standard deviation of Negative control 
14. Interpretation 
 Strong  ->4 times ODC 
 Moderate -  2 times the ODC- 4 Times ODC 
 Weak    -  2 x ODC 
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Determination of Extended spectrum beta lactamase (ESBL) production  
Screening test [45] 
All Gram negative isolates were screened with Two disk Cefotaxime 30µg 
and Ceftazidime 30µg and considered to be ESBL producers if Zone of inhibition 
for 
Cefotaxime 30µg- 27 mm 
Ceftazidime 30µg   -    22 mm 
These isolates were subjected to phenotypic confirmatory test. 
Lawn culture of the isolates were made on Mueller Hilton agar plate. 
Ceftazidime 30µg, Ceftazidime- Clavulanate 30µg/10µg disks and 
Cefotaxime30µg, Cefotaxime-Clavulanate 30µg/10µg  disks  were placed and 
incubated at 37ºC for 18 hours. 
INTERPRETATION 
An increase in Zone of inhibition by  5 mm diameter for either 
antimicrobial agent tested in combination with ȕ Lactamase inhibitor was confirmed 
as ESBL producer. 
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DETERMINTAION OF AmpC production[37] 
SCREENING TEST 
All Gram negative isolates were screened with cefoxitin30µg disk for AmpC 
production. 
Lawn culture of the isolates were made on Mueller Hilton agar plate 
Cefoxitin30µg disk were placed and incubated at 37ºC for 18 hours. 
INTERPRETATION 
Zone of inhibition by 18 mm diameter for cefoxitin was taken as  Amp C 
production . 
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                                        RESULTS 
This study was done on 100 patients with venous  leg ulcers and results were 
analysed statistically using SPSS version  2.1. 
TABLE 1: AGE WISE DISTRIBUTION OF CASES (n=100) 
Years No of cases Males Females 
Percentage
% 
Below 30  6 6 - 6 
31-40 14 12 2 14 
41-50 20 17 3 20 
51-60 24 20 4 24 
61-70 29 22 7 29 
 71 7 7 - 7 
TOTAL 100 84 16  
 
Out of 100 cases, twenty nine cases were found in the age group of 61-70 
years, followed by 51-60 years age group.  
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Out of 100 patients,Eighty four were Males and sixteen were females.  
 
84
16
CHART 2:GENDER WISE 
DISTRIBUTION (n=100)
MALES
FEMALES
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TABLE 2: The anatomical distribution of the venous ulcers (n=100) 
Anatomical Location No of Ulcers Percentage 
Above Medial  Malleolus 81 81 
Above lateral  Malleolus 17 17 
Gaiter region 2 2 
Total 100  
 
Most common position of the Ulcers was above the Medial malleolus.This 
corresponds to the anatomy and pathology of the Venous ulcers 
TABLE 3: Comorbid conditions in the study population (n=100) 
Diseases Number Percentage 
Diabetes mellitus 18 18 
Hypertension 4 4 
Diabetes/Hypertension 4 4 
Obesity 12 12 
Co morbid Cardiac diseases 4 4 
Chronic renal failure 1 1 
Herniorhaphy 3 3 
No associated comorbid conditions 54 54 
Total 100  
 
Out of 100 patients, twelve patients were obese (above 90 kgs). 
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TABLE 4 : Occupation of the Patients (n=100) 
Type of Occupation No of patients Percentage 
Security workers 21 21 
Daily wagers 17 17 
Farmers 10 10 
Cooks in hotels 9 9 
Tailors 9 9 
Vendors 8 8 
Supervisors 4 4 
Others 22 22 
Total 100 100 
 
Among the occupation of the study population, 21 were security workers.17 
were daily wagers 
         TABLE 5: Personal habits of the patients (n=100) 
Habits No of cases Percentage 
Alcoholics 21 21 
Smoker 9 9 
Alcoholic/smoker 25 25 
No habits 45 45 
Total 100  
 
Out of 100 patients   25 were both alcoholics  and  smokers. 
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TABLE 6:  Association With Venous Pathology(n=100) 
Venous pathology No of cases Percentage P value 
DVT 10 10 0.001* 
Operated either for Varicose 
veins or SSG done  
16 16 0.001* 
Visible Varicose Veins 66 66 0.001* 
IVC thrombosis operated 1 1  
No pathology 7 7  
Total 100 100  
 
Ten patients were treated for Deep Vein thrombosis (DVT).Sixteen patients 
were either operated for varicose veins or had split skin grafting done for the 
ulcer.66 patients had varicose veins. 
TABLE 7: Results of doppler study among the study population.(n=100) 
Venous pathology No of cases Percentage 
Great Saphneous Vein Pathology 22 22 
Short saphaneous Vein 
Pathology 
35 35 
Perforator Incompetence (Above 
ankle ,Below Knee, Mid calf, 
Above Knee) 
43 43 
Total 100 100 
Perforator Incompetence was found in 43 patients. 
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TABLE 8: Clinical Signs And Symptoms Of Study Population (n=100) 
Complaints No of cases Percentage 
Increased  Pain 46 46 
Swelling 5 5 
Discharge 15 15 
Discharge with Malodour  5 5 
Pain and Discharge 26 26 
Pain and Swelling and Fever 3 3 
Total 100 100 
 
 The clinical spectrum of the patients were Increased pain,followed by pain 
and discharge from the wound.Five patients had swelling  and three had Fever. 
Increased  
Pain
46%
Swelling
5%
Discharge
15%
Discharge 
with 
Malodour 
5%
Pain and 
Discharge
26%
Pain and 
Swelling 
and Fever
3%
CHART 3:Clinical SIGNS AND 
SYMPTOMS
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 TABLE 9: Correlation of Gram Stain to Culture Positivity 
Direct Gram stain   was used as screening test for quantitative culture. 
(n=100) 
 Culture Positive Culture 
Negative 
significance 
Smear positive 
(Organism ±Pus cells) 
53 - P<0.001 
Smear negative 
(No Organism ± Pus 
cells) 
38 9  
 
From 100 venous ulcer patients, One hundred and thirty nine bacterial 
organisms were isolated. 
TABLE 10: Microbial Distribution in Ulcers (n=100) 
No of Organisms No of ulcers No of isolates Percentage 
Monomicrobial 46 46 46 
Polymicrobial 45 93 45 
No Growth 9   
Total 100 139  
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46
45
9
Chart 4:Microbial distribution in 
Ulcers (n=100)
Monomicrobial
Polymicrobial
No Growth
 
TABLE 11: TOTAL NUMBER OF ISOLATES (n=139) 
Name of the Organism No of isolates Percentage (%) 
Staphylococcus aureus 37 26.6 
Staphylococcus epidermidis 9 6.4 
Streptococcus pyogenes 3 2.1 
Enterococcus faecalis 8 5.7 
Enterococcus faecium 1 0.71 
Micrococci 6 4.3 
Diptheroids 6 4.3 
Escherichia coli 14 10.07 
Klebsiella  oxytoca 5 3.5 
Klebsiella  pneumoniae 3 2.1 
Proteus  mirabilis 10 7.1 
Proteus  vulgaris 6 4.3 
Pseudomonas  aeruginosa 15 11.1 
Acinetobacter  baumanii 2 1.4 
Peptostreptococcus anaerobicus 12 8.6 
Bacteriodes  fragilis 2 1.4 
Total 139  
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Chart 5:MICROBIAL PATTERN (n=139)
organisms
 
Staphylococcus aureus was the commonest organism to be isolated. Out of 
139 organisms isolated,37 were Staphylococcus aureus. 
Out of 139 isolates, Forty two aerobic isolates were found to have         
colony counts  106CFU/gram tissue and 14 anaerobes were isolated . 
Table 12:   Distribution of Infection in the ulcers(n=100) 
Type of Ulcer No of Ulcers Infected Ulcers Percentage 
Monomicrobial   46 20 20 
Polymicrobial  45 28 28 
No growth 9   
Total 100 48  
 
 
 
 
58 
 
TABLE 13:   Distribution of Pathogens (n=56) 
Type of ulcer 
No of Pathogens 
Percentage 
Aerobes Anaerobes 
Monomicrobial Ulcer 20 - 35.71 
Polymicrobial ulcers 22 14 64.29 
Total (n=56) 42 14  
 
Anerobes were isolated from 14 ulcers. 
20
28
Chart 6:Distribution of Ulcers with 
Pathogens (n=48)
Monomicrobial Ulcer
Polymicrobial ulcers
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                                   Distribution  of Pathogens in the Ulcers (n=56) 
23
19
12
2
Chart 7:Distribution of Pathogens 
(n=56)
Aerobic GPC
Aerobic GNB
Anaerobic GPC
Anaerobic GNB
 
TABLE 14:  Distribution of Aerobic Pathogens (106CFU/gram tissue) among 
the ulcers (n=42) 
Organism 
Monomicrobial 
Ulcers 
Polymicrobial  
Ulcers 
Total % 
Staphylococcus aureus 12 5 17 40.47 
Staphylococcus 
epidermidis 
1  1 2.3 
Streptococcus pyogenes 2 1 3 7.14 
Enterococcus faecalis  2 2 4.7 
Escherichia coli  2 6 8 19.04 
Proteus vulgaris  1 1 2.3 
Proteus mirabilis  3 3 7.14 
Klebsiella  oxytoca 1 1 2 4.7 
Pseudomonas 
aeruginosa 
2 3 5 11.9 
Total (n=42) 20 22 42  
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The pathogenicity was determined by the colony count.           
Staphylococcus aureus was found to be pathogen in 17 ulcers .Out of 17 
Staphylococcus aureus isolates, 13  were methillicin resistant .ESBL producers 
were found in seven ulcers. 
Streptococcus pyogenes was isolated in three cases. It was found to be single 
organism infecting the wound in two ulcers. Streptococcus pyogenes were taken as 
pathogen irrespective of colony count. 
Chart 8: Distribution of aerobic Pathogens (n=42) 
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Chart 9: Distribution of infection  and colonization in ulcers (n=100) 
48
43
9
Ditribution of infection in 
Ulcers
Infected ulcer
Colonised
no growth
 
Out of 100 ulcers, 43 % was found to be colonized ( 105CFU/gram tissue). 
In 43 ulcers, 83 aerobic isolates were found to be colonizers (59.7%). 
Table 15: Distribution of Colonisers (n=83) 
Name of Organism No of isolates Percentage 
Staphylococcus aureus 20 24.8 
Staphylococcus epidermidis 8 9.6 
Enterococcus faecalis 6 7.2 
Enterococcus faecium 1 1.2 
Micrococci 6 7.2 
Diptheroids 6 7.2 
Escherichia coli 6 7.2 
Klebsiella  oxytoca 3 3.6 
Klebsiella  pneumoniae 3 3.6 
Proteus mirabilis 7 8.4 
Proteus vulgaris 5 6.02 
Pseudomonas  aeruginosa 10 12.4 
Acinetobacter baumanii 2 2.4 
Total 83  
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IDENTIFICATION OF ANAEROBES 
Fourteen  Anaerobes were isolated from  fourteen ulcers.They were  isolated  
along with the aerobic  organism in the ulcers. Peptostreptococcus anaerobicus was 
isolated from 12 ulcers and Bacteroides fragilis from two ulcers. The Quantification 
was not done for anaerobes. 
TABLE 16:  Distribution of the anaerobes (n=14) 
Organism No of cases 
Peptostreptococcus 
anaerobicus 
12 
Bacteroides  fragilis 2 
Total 14 
 
12
2
Chart 10 :Anaerobes (n=14)
Peptostreptococcus
anaerobicus
Bacteroides fragilis
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TABLE 17: Duration of the venous ulcers (n=100) 
Duration No of cases 
Infected 
cases(n=48) 
Percentage 
Below 1 year 4 2 4 
1-5 years 35 16 35 
6-10 years 36 20 36 
11-15 years 18 7 18 
 16 years 7 3 7 
Total 100 48 100 
 
Out of 100 patients, thirty six patients had ulcer for  6-10 years 
duration.Seven patients had the ulcer for more than 16 years. Out of 36 ulcers in  6-
10 Years of duration, 20 ulcers were found to  be infected. The duration of ulcer did 
not correlate with the infection. 
P valve is < 0.038. It is not significant. 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE ISOLATES. 
Antimicrobial susceptibility pattern of the isolates were determined  by disk 
diffusion method and MIC determination for Vancomycin and interpreted according 
to the CLSI guidelines. Antimicrobial susceptibility pattern was not done for 
Anaerobes.Micrococci were taken as normal skin commensals. 
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ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE ISOLATES. 
TABLE 18: Gram Positive Organisms(n=64) 
ORGANISM PEN 10µg 
ERY 
15µg 
AK 
30µg 
CIP 
5µg 
 
COT 
1.25/23.75 
µg 
CX 
30µg 
GM 
10µg 
TET10
µg 
VAN 
30µg 
 
CL 
2µg* 
HLG 
120 µg 
S.aureus (MSSA) 
(24) 
100% 
(24) 
79.2% 
(19) 
87.5% 
(21) 
62.5% 
(16) 
70.8% 
(17) 
100% 
(24) 
83.3% 
(20) 
91% 
(22) 
NT 100% 
(24) 
NT 
S.aureus (MRSA) 
(13) 
0% 
(13) 
30% 
(4) 
76.9 
(10) 
61.5% 
(8) 
23.8% 
(3) 
0% 
(13) 
69.8% 
(9) 
30% 
(4) 
NT 100% 
(13) 
NT 
S.epidermidis 
(9) 
100% 
(9) 
100% 
(9) 
77.7% 
(7) 
66.6% 
(6) 
66.6% 
(6) 
100% 
(9) 
66.6% 
(6) 
88.8% 
(8) 
NT 100% 
(9) 
NT 
Streptococcus 
Pyogenes 
(3) 
100% 
(3) 
100% 
(3) 
NT 100% 
(3) 
NT NT NT 100% 
(3) 
100% 
(3) 
100% 
(3) 
NT 
Enterococcus faecalis 
(8) 
100% 
(8) 
62.8% 
(5) 
NT 100% 
(8) 
NT NT NT NT 100% 
(8) 
NT 100% 
(8) 
Enterococcus 
faecium 
(1) 
100% 
(1) 
100% 
(1) 
NT 0% 
(0) 
NT NT NT NT 100% 
(1) 
NT 100% 
(1) 
Diphtheroids** 
(6) 
100% 
(6) 
NT NT 100% 
(6) 
NT NT NT NT 100% 
(6) 
NT NT 
 
 
*Clindamycin sensitivity was reported after testing with Inducible D test according to    the CLSI guidelines. 
** Sensitivity to Diphtheroids were interpreted according to British Society ofAntimicrobial Chemotherapy guidelines.Micrococci  
were treated as normal skin commensals. 
KEY TO THE TABLE 
PEN- Penicillin, ERY- Erythromycin, AK-Amikacin, CIP-Ciprofloxicin, COT-Cotrimoxazole, CX-Cefoxitin,GM-
Gentamicin,TET-Tetracycline,VAN-Vancomycin,CL-Clindamycin,HLG- High level gentamicin 
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ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE ISOLATES. 
TABLE 19: Gram Negative Bacilli(n=55) 
Organism 
AK 
30µg 
 
CIP 
5µg 
 
COT 
1.25/23.75 
µg 
PT 
100/10 
µg 
CAZ 
30 µg 
CTX 
30 µg 
GM 
10µg 
TET 
10µg 
IMP 
10 µg 
CX 
30 µg 
E.Coli 
(14) 
92.8 
(13) 
85.75% 
(12) 
57.14% 
(8) 
100% 
(14) 
57.14% 
(8) 
57.14% 
(8) 
85.75% 
(12) 
85.75% 
(12) 
100% 
(14) 
100% 
(14) 
K.oxytoca 
(5) 
60% 
(3) 
60% 
(3) 
60% 
(3) 
80% 
(4) 
80% 
(4) 
80% 
(4) 
60% 
(3) 
60% 
(3) 
100% 
(5) 
100% 
(5) 
K.pneumoniae 
(3) 
33.3% 
(1) 
66.6% 
(2) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
33.3% 
(1) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
Proteus vulgaris 
(6) 
100% 
(6) 
66.6% 
(4) 
83.3% 
(5) 
100% 
(6) 
100% 
(6) 
100% 
(6) 
83.3% 
(5) 
100% 
(6) 
100% 
(6) 
100% 
(6) 
Proteus mirabilis 
 (10) 
90% 
(9) 
80% 
(8) 
70% 
(7) 
100% 
(10) 
100% 
(10) 
100% 
(10) 
80% 
(8) 
70% 
(7) 
100% 
(10) 
100% 
(10) 
Pseudomonas aeruginosa 
(15) 
73.3% 
(11) 
60% 
(9) 
NT 100% 
(15) 
100% 
(15) 
NT 66.6% 
(10) 
NT 100% 
(15) 
100% 
(15) 
Acinetobacter 
baumanii 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
 
 KEY TO THE TABLE 
 AK-Amikacin,CIP-Ciprofloxicin,COT-Cotrimoxazole, CX-Cefoxitin,GM-Gentamicin,TET-Tetracycline,PT-Piperacillin- 
Tazobactam,CAZ-Ceftazidime,CTX-Cefotaxime, IMP- Imipenam 
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                          ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE AEROBIC PATHOGENS (n=42) 
 
TABLE 20: Gram Positive Organisms (n=23) 
Organism PEN 10µg 
ERY 
15µg 
AK 
30µg 
CIP 
5µg 
 
COT 
1.25/23.
75 µg 
CX 
30µg 
GM 
10µg 
TETR 
10µg 
VAN 
30 µg 
CL* 
2µg* 
HLG 
120 µg 
S.aureus (MSSA) 
(4) 
100% 
(4) 
75% 
(3) 
75% 
(3) 
50% 
(2) 
50% 
(2) 
100% 
(4) 
75% 
(3) 
75% 
(3) 
NT 100% 
(4) 
NT 
S.aureus (MRSA) 
(13) 
0% 
(13) 
30% 
(4) 
76.9 
(10) 
61.5% 
(8) 
23.8% 
(3) 
0% 
(13) 
69.8% 
(9) 
30% 
(4) 
NT 100% 
(13) 
NT 
Streptococcus 
Pyogenes 
(3) 
100% 
(3) 
100% 
(3) 
NT 100% 
(3) 
NT NT NT 100% 
(3) 
100% 
(3) 
100% 
(3) 
NT 
Enterococcus 
faecalis(2) 
100% 
(2) 
100% 
(2) 
NT 100% 
(2) 
NT NT NT 
 
 
NT 100% 
(2) 
NT 100% 
(2) 
Staphylococcus 
epidermidis (1) 
100% 
(1) 
100%(1) 100%
(1) 
0% 
(0) 
0% 
(0) 
100%
(1) 
100%
(1) 
100% 
(1) 
100%
(1) 
100% 
(1) 
NT 
 
*Clindamycin susceptibility   was reported after testing with Erythromycin for inducible resistance by  D test 
KEY TO THE TABLE 
PEN- Penicillin, ERY- Erythromycin, AK-Amikacin, CIP-Ciprofloxicin, COT-Cotrimoxazole, CX-Cefoxitin,GM-
Gentamicin,TET-Tetracycline,VAN-Vancomycin,CL-Clindamycin,HLG- High level gentamicin 
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ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE AEROBIC PATHOGENS(n=42) 
TABLE 21: Gram Negative Bacilli (n=19) 
Organism 
AK 
30µg 
 
 
CIP 
5µg 
 
COT 
1.25/23.75 
µg 
PT 
100/10 
µg 
CAZ 
30 µg 
CTX 
30 µg 
GM 
10µg 
TET 
10µg 
IMP 
10 µg 
CX 
30 µg 
E.Coli 
(n=8) 
75% 
(6) 
87.5% 
(7) 
62.5% 
(5) 
100% 
(8) 
25% 
(2) 
25% 
(2) 
75% 
(6) 
87.5% 
(7) 
100% 
(8) 
100% 
(8) 
K.oxytoca 
(n=2) 
50% 
(1) 
0% 
(0) 
0% 
(0) 
50% 
(1) 
50% 
(1) 
50% 
(1) 
50% 
(1) 
50% 
(1) 
100% 
(2) 
100% 
(2) 
Proteus mirabilis 
(n=3) 
100% 
(3) 
100% 
(3) 
66.6% 
(2) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
66.6% 
(2) 
33.3% 
(1) 
100% 
(3) 
100% 
(3) 
Proteus vulgaris 
(n=1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
100% 
(1) 
Pseudomonas 
aeruginosa 
(n=5) 
100 % 
(5) 
60% 
(3) 
NT 100% 
(5) 
100% 
(5) 
NT 80% 
(1) 
NT 100% 
(5) 
100% 
 
KEY TO THE TABLE 
 AK-Amikacin,CIP-Ciprofloxicin,COT-Cotrimoxazole, CX-Cefoxitin,GM-Gentamicin,TET-Tetracycline,PT-Piperacillin- 
Tazobactam,CAZ-Ceftazidime,CTX-Cefotaxime, IMP- Imipenam 
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                                   ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE COLONISERS     (n=77) 
TABLE 22: Gram Positive Organisms    (n=41) 
ORGANISMS PEN 10µg 
ERY 
15µg 
AK 
30µg 
CIP 
5µg 
 
COT 
1.25/ 
23.75 
µg 
CX 
30µg 
GM 
10µg 
TET 
10µg 
VAN 
30 µg 
CL* 
2µg 
HLG 
120 µg 
S.aureus (MSSA) 
(20) 
100% 
(20) 
80% 
(16) 
90% 
(18) 
65% 
(13) 
75% 
(15) 
100% 
(20) 
85% 
(17) 
95% 
(19) 
NT 100% 
(20) 
NT 
S.epidermidis 
(8) 
100% 
(8) 
100% 
(8) 
75% 
(6) 
75% 
(6) 
75% 
(6) 
100% 
(8) 
62.5% 
(5) 
87.5% 
(7) 
NT 100% 
(8) 
NT 
Enterococcus 
faecalis 
(6) 
100% 
(6) 
50% 
(3) 
NT 100% 
(6) 
NT NT NT NT 100% 
(6) 
NT 100% 
(6) 
Enterococcus 
faecium 
(1) 
100% 
(1) 
100% 
(1) 
NT 0% 
(0) 
NT NT NT NT 100% 
(1) 
NT 100% 
(1) 
DIPHTHEROIDS 
(6) 
100% 
(6) 
NT NT 100% 
(6) 
NT NT NT NT 100% 
(6) 
NT NT 
*Clindamycin sensitivity is reported by  inducible D test according to the CLSI guidelines. 
KEY TO THE TABLE 
PEN- Penicillin, ERY- Erythromycin, AK-Amikacin, CIP-Ciprofloxicin, COT-Cotrimoxazole, CX-Cefoxitin,GM-Gentamicin,TET-
Tetracycline,VAN-Vancomycin,CL-Clindamycin,HLG- High level gentamicin 
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                                     ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF THE COLONISERS     (n=77) 
TABLE 23: Gram Negative Bacilli (n=36) 
Organisms 
AK 
30µg 
 
 
CIP 
5µg 
 
COT 
1.25/23.75 
µg 
PT 
100/10 
µg 
CAZ 
30 µg 
CTX 
30 µg 
GM 
10µg 
TET 
10µg 
IMP 
10 µg 
CX 
30 µg 
E.Coli 
(6) 
100% 
(6) 
83.3% 
(5) 
50% 
(3) 
100% 
(6) 
100% 
(6) 
100% 
(6) 
83.3% 
(5) 
83.3% 
(5) 
100% 
(6) 
100% 
(6) 
K.oxytoca 
(3) 
66.6% (2) 60% 
(3) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
66.6% 
(2) 
66.6% 
(2) 
100% 
(3) 
100% 
(3) 
K.pneumoniae 
(3) 
33.3% 
(1) 
66.6% 
(2) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
33.3% 
(1) 
100% 
(3) 
100% 
(3) 
100% 
(3) 
Proteus vulgaris 
(5) 
100% 
(5) 
60% 
(3) 
80% 
(4) 
100% 
(5) 
100% 
(5) 
100% 
(5) 
80% 
(4) 
80% 
(4) 
100% 
(5) 
100% 
(5) 
Proteus mirabilis 
 (7) 
85.8% 
(6) 
71.4% 
(5) 
71.4% 
(5) 
100% 
(7) 
100% 
(7) 
100% 
(7) 
85.8% 
(6) 
85.8% 
(6) 
100% 
(7) 
100% 
(7) 
Pseudomonas 
aeruginosa 
(10) 
60% 
(6) 
60% 
(6) 
NT 100% 
(10) 
100% 
(10) 
NT 50% 
(5) 
NT 100% 
(10) 
NT 
Acinetobacter 
baumanii 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
100% 
(2) 
KEY TO THE TABLE 
 AK-Amikacin,CIP-Ciprofloxicin,COT-Cotrimoxazole, CX-Cefoxitin,GM-Gentamicin,TET-Tetracycline,PT-Piperacillin- Tazobactam,CAZ-
Ceftazidime,CTX-Cefotaxime, IMP- Imipenam 
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TABLE 24: Methicillin Resistance Among Staphylococcus aureus Isolates By 
Cefoxitin Screening Method (n=37) 
 No of isolates Percentage 
MSSA 24 64.84 
MRSA 13 34.16 
TOTAL 37  
 
24
13
Chart 11:MSSA AND MRSA (n=37)
MSSA
MRSA
 
 All the isolates were susceptible to Vancomycin by MIC macrobroth  
dilution method. 
 MIC was  2µg/ml. 
There was no resistance to Clindamycin  by Inducible D test  done according 
to CLSI guidelines. 
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Biofilm Production among MRSA isolates 
Biofim formation was determined among MRSA isolates by microtitre plate 
method. The results were interpreted by following formula. 
ODC (Optical density Cutoff) value was calculated with the formula 
ODC= Mean of the Negative Control+ 3 x Standard deviation of Negative 
control.  
ODC= 0.069 
Moderate Biofilm producers had OD value above .0.207 OD 
Using the given formula, Out of 13 MRSA isolates, Five were found to be Moderate 
Biofilm producers. Others were Weak biofilm producers 
TABLE 25 : Biofilm Producers Among MRSA Isolates (n=13) 
Type of Biofilm No of cases Percentage 
Strong producers NIL 0 
Moderate biofilm 
producers 
5 38.4 
 
Weak Biofilm 
producers 
8 61.5 
Total 13  
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TABLE 26 : Vancomycin Susceptibility Among The Methicillin Resistant 
Staphylococcus aureus By Macrobroth Dilution Method (n=13) 
 
Vancomycin MIC2 µG/ML MIC 4-8 µG/ML MIC <16 µG/ML 
MRSA 13 NIL NIL 
 
All thirteen isolates were susceptibile to Vancomycin by MIC macrobroth 
dilution method. 
TABLE 27: Resistant Pattern In Enterobacteriaceae Isolates (n=38) 
 
Organism 
 
Total no 
ESBL 
producers 
Percentage 
Escherichia coli 
 
14 6 15.7% 
Klebsiella 
oxytoca 
 
5 1 2.6% 
Klebsiella 
pneumoniae 
 
3 nil  
Proteus vulgaris 
 
6 nil  
Proteus 
mirabilis 
 
10 nil  
Total 
 
38 7  
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Chart 12: Distribution of ESBL producers (n=7) 
 
Among the 19 Isolates of Escherichia coli and Klebsiella  oxytoca, Seven 
were ESBL Producers by Screening Test with CTX and CAZ disk .They were 
confirmed by Phenotypic confirmatory test 
There was no Amp C and MBL producers in this study. 
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DISCUSSION 
This cross sectional study was conducted at the Institute of Microbiology, 
Madras Medical College in association with the department of  General 
surgery,Vascular surgery, Plastic surgery, Rajiv Gandhi Government General 
Hospital  and Madras Medical College,Chennai. 
100 patients with venous leg  ulcers  who satisfied the inclusion criteria were 
included in the study. 
In this study,29% of the patients were found in the age group of 61-70, 
followed by the  51-60 years (24%).(Table:1). Venous insufficiency progresses with 
age.[51]The prevalence of venous ulcer had been found to increase by 4% over the 
age of 65 years[5]. In the article Contemporary reviews in Cardiovascular medicine, 
Robert T. Eberhardt, MD; Joseph D. Raffetto, MD quote that the incidence 
increases with age more than fifty[52] . 
Female sex is a clinically accepted risk factor for chronic venous diseases.[53]  
Explanation is probably that the females outlive males.[51] In our  study,among  100 
patients  with Venous ulcer,84% were males and 16 %were females.  (Table :1) 
Most of the patients in this study had  occupation  related to standing for long 
hours resulting in venous hypertension[54].21% of the study population were night 
security workers followed by daily wagers (17%).In the  article by by D. J.  Radak 
and V. A. Sotirovic, et al on  their study on  risk factors for symptomatic chronic 
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venous disorders quote that profession related to prolonged  sitting or standing  was 
found to have  increased risk for Chronic venous disease.[55](Table :4) 
 In the study by Dragan J.  Milic,  PhD, Sasa S. Zivic, et al ,the risk factor of 
healing was the presence of a non healing ulcer of more than 12 months .But no 
correlation is given for the duration of ulcer and infection rate.[56] In this study, 36% 
of the patients had the Venous ulcers for a period of 6-10 years (table:) but the 
frequency of the infection  did not correlate with the duration of the ulcers.      
(Table :17)  
Calf muscle pump dysfunction leads to venous hypertension which in turn 
leads to venous dysfunction and stasis of blood at lower limbs. In this study, GSV, 
SSV and perforator incompetence were associated with venous ulcers. 81% percent 
of the venous ulcers were above the medial malleolus and 43 % had perforator 
incompetence. In  the study by  Georgios Spentzouris and Nocos Labropoulos et al, 
the incidence of the location of ulcer above the medial malleolus was reported to be  
95%[57] (Table:7). 
 BMI value higher than 33 kg/m2 is quoted as a risk factor for chronic venous 
ulcers[56].Obesity leads to dysfunction of valves leading to poor venous return.In 
this study  12% of the patients were found to be obese.(p value is <0.001 which is 
significant) (Table :3)  
Deep vein thrombosis and varicose veins leads to venous insufficiency and 
venous hypertension and causes venous ulcers in the lower limbs.Deep vein 
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thrombosis (DVT) causes damage to the valves.In the current study, 66% had 
visible varicose veins, 10 % of the patients  had DVT and 16 % of the study 
population  had previous surgeries  associated with the  venous ulcer. In the study 
by Dragan J. Milic, PhD,Sasa S. Zivic,et al,the incidence  of DVT was 36% among 
the venous ulcer patients.[56] (Table:6)Smoking increases the risk for venous 
ulceration[58].Avoiding smoking and alcohol abstinence gives better results of 
compression therapy and pain management[59] In the study,25% of the  study 
population  were alcoholic and smokers.9% were smokers.(Table:5) 
Venous stasis and inflammation stimulates the peripheral nerve endings 
Superadded infection worsens it.The increased pain is sign of infection.[6].46% of 
the  patients  in the current study had pain and 26% had discharge. 5%had 
malodourous discharge.In the study by Howell et al ,61% of the patients presented 
with increased pain[30].(Table :8). 
 Direct gram stain correlated with Quantitative culture in 53% of the 
ulcers.Direct Gram stain is a  rapid  indication  of the bacterial burden in the wound 
P.G.  Bowler  et  al  states  that  a  rapid  Gram  stain  technique  is  shown  to   predict  a  
microbial load of >105 CFU/g  of  tissue  if  a  single  microorganism  is  seen  on  the  
slide preparation”.[26]Levine et al also concluded  that the presence of bacteria in 
Gram stain is  associated with  106 bacteria or more per swab present.[60](Table :9) 
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Robson et al. have suggested that “quantitative bacterial counts from tissue 
biopsy samples of the ulcer 106CFU /gram tissue indicates infection”[72][17].In this 
study, this criteria was followed to assess the bacterial burden in the clinically 
infected ulcers.According to the results of Quantitative culture,48 % of the ulcers 
were found to be infected.Among this,20% of ulcers had single organism isolated. 
28 % of the cases  had polymicrobial infection. The remaining  43% of the ulcers 
were considered as colonizers with either single or multiple organisms as the 
quantitative culture yielded < 106CFU/gram tissue. There was no growth in 9% of 
the ulcers.This is in contrast to the study conducted by Somaprakas et al,90 % of the 
ulcers were found to be monomicrobial[61].  In  the  study by Brook et  al  on  aerobic  
and anaerobic microbiology of chronic venous ulcers,they concluded that chronic 
venous ulcers are polymicrobial with aerobic and anaerobic flora[62].More than one 
bacterial species were detected by  Kritine et al in their study on multiple bacterial  
species residing in the chronic wounds.[63](Table :12) 
Among the aerobes, Gram positive cocci were the predominant pathogen 
among the infected venous ulcers. Among the Gram positive cocci,   
Staphylococcus aureus was the commonest pathogen isolated  from 17% of the 
ulcers  followed by Streptococcus pyogenes in 3% of the ulcers.            
Streptococcus pyogenes infection  presents with inflammation  and spreads along 
the draining lymphatics to focal lymph nodes and rapidly through subcutaneous 
tissue and fascia with rapid tissue destruction[64].Madsen  et  al  in  their  study  on  
bacterial  colonization  and   healing  of  venous  ulcers  found  that  ulcers  with  
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Staphylococcus and beta haemolytic Streptococcus healed slowly.[65]Enterococcus 
faecalis are normal flora of the skin. It is implicated in wound infections. In our 
study, Enterococcus faecalis were isolated from 2% of the ulcers and 
Staphylococcus epidermidis  from  1%  of  the  venous  ulcer.  In  study  by  Mustafa  
Fazli,et al,Staphylococcus  aureus in 50% of the cases [66] Bowler et al in their study 
concluded that, Staphylococcus aureus was the commonest organism to be 
isolated[73].(Table:14) 
 Among the Gram negative bacilli, Escherichia coli was  the commonest 
pathogen  (8%) followed by Pseudomonas aeruginosa (5%). Brook and Frazier et al 
reported an isolated rate of 12% for  Escherichia coli .[62](Table :14)  
 Out  of  37  Staphylococcus aureus isolates,35.1%  was Methicillin resistant 
Staphylococcus aureus (MRSA). In a study conducted in Brazil, the frequency of 
MRSA   was  28%. [67]. It is almost impossible to eradicate MRSA from chronic 
wounds.[69]Howell –jones quotes that with MRSA infection, problems include 
cross-contamination of wounds from the patients themselves, fomites and  health 
care personnel[30]. In the study by Frankel et al, the incidence of MRSA was  45%  
among  patients with chronic wounds.[74] (Table:24) 
 Chronic wound does not heal despite adequate treatment due to the presence 
of biofilm. In this study, 38.4% of MRSA isolates were moderate biofilm producers. 
Biofilm in MRSA isolates makes them resistant to antibiotics and  is due to 
presence of polysaccharide intracellular antigen.[61] Biofilm formation and 
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adherence of bacteria to host tissue are one of the most important virulence factors 
of methicillin-resistant strains of Staphylococcus aureus (MRSA).[70]In the study 
done in Brazil,45% of MRSA isolates from the chronic wounds were moderate 
biofilm producers[70] which correlated with this  study.(Table :25) 
30% of the MRSA isolates were susceptible to  Erythromycin and  all were 
susceptible to clindamycin by inducible D test.In the study by Martin et al  
Erythromycin and clindamycin  resistance was 69.6% .60% of  cases showed 
inducible clindamycin resistance[67].The absence of inducible clindamycin 
resistance in our study could be due to the rare usage of the drug as first line of 
treatment in our  hospital. 
All the MRSA isolates were susceptible to Vancomycin tested by 
determination of Minimum Inhibitory concentration by Macro broth dilution 
method. (Table :26) 
 Among the 38 isolates of Enterobactericeae, 18.3% were ESBL producers by 
phenotypic confirmatory method.Six isolates of Escherichia coli were ESBL 
producers. Among the two Klebsiella oxytoca isolates , one was an ESBL producer. 
In  study  conducted  by  Nyambura  Moremi  et  al  41%  were  ESBL  producers  
(Escherichia coli  and Klebsiella species)[68]. No other significant resistance pattern 
was found among the pathogens in the current study. (Table:27) 
 Colonisers are bacteria whose multiplication causes little or no harm to the 
host.  Though bacterial quantity and virulence define colonization, harmful or 
 
 
 
80 
 
harmless colonization  depends on  the local and general resistance of the host. 43% 
of the ulcers were found to be colonized with bacteria.  26% of the ulcer was 
colonized by single organism.17% were polymicrobial. 
Staphylococcus aureus was the commonest organism to be isolated among 
colonisers in 20% of the ulcers. In the study conducted by Bowler et al  on 
microbiology of infected and non infected leg ulcers in 1999,Staphylococcus aureus 
was the commonest organism to be isolated in non infected ulcers. (Table :15)[73] 
 Among the colonisers,the most common  Gram negative bacilli isolated was 
Pseudomonas aeruginosa  (10%) followed by Proteus mirabilis in 7%,Escherichia  
coli in 6%,Acinetobacter baumanii in 2%.Halbert et al found no significant delay in 
the wounds colonized by Pseudomonas aeruginosa.[71l] These  organisms were 
found  susceptible to all antibiotics tested. This differs from the study conducted in 
Eastern India, where MBL producing strain of Acinetobacter baumanii and 
Acinetobacter lwoffi were isolated from venous ulcer. [29] 
The only significant antimicrobial resistance among colonisers was found in 
Klebsiella pneumoniae which showed 33% susceptibility to Aminoglycosides 
(Table :23)  
 The anaerobes were isolated from 14 % of the ulcers in this study. They were 
found in synergy with the aerobes. The tissue hypoxia caused by aerobes serves as 
suitable environment for anaerobes to grow[26]. Peptostreptococcus anaerobicus 
was isolated in12% of the  ulcers followed by Bacteroides  fragilis in 2% .  In  a  
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study by Brook et al on aerobic and anaerobic microbiology of chronic venous 
ulcers ,the anaerobes were isolated in 53.6%  of  cases[62]. Anaerobic isolation rate 
of 17% was reported in the study by Halbert et al .[71] (Table :16) 
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                                                   SUMMARY 
x  100 venous leg ulcer patients with clinical signs of infection attending the 
Department of General, Plastic and Vascular surgery departments were 
included in the study. 
x Two tissue bits were obtained from the patients for aerobic Quantitative 
culture and for isolation and identification of anaerobes. 
x Out of 100 patients, 29 %were found in the age group 61-70 years. 84 %were 
males and 16% were females. Commonest anatomical location was above 
medial malleolus (81%). Perforator dysfunction was observed in 43% of 
patients. 46% of patients presented with increased pain. 36% ulcers were of 
6-10 years duration. 
x Risk factors associated with the ulcers were occupation, Deep vein 
thrombois, obesity, Varicose veins, 
x Increased pain was the main presenting symptom (46%) 
x Gram stain correlated with positive quantitative culture in 53% of the ulcers. 
x Out of 100 ulcers, 91% of them were culture positive. 48% of the ulcers were 
infected.43% were colonized.9% showed no growth.Out of 48% of infected 
ulcers, single organism was isolated from 20 % of ulcers. 28% of the   ulcers 
were polymicrobial. 
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x Gram positive cocci were the predominant pathogen in infected ulcers. 
Staphylococcus aureus was the commonest organism to be isolated in 17%of 
the ulcers  followed by Escherichia coli in 8%. Streptococcus pyogenes was 
found to be the etiological agent in 3% of the ulcers 
x Methicillin resistant Staphylococcus aureus were  isolated  from 13% of  the  
ulcers. All the MRSA isolates were susceptible for Vancomycin. Out of 13 
MRSA isolates, 5 were moderate biofilm producers. 
x Among the 38 Enterobacteriaceae isolates, 18.3% were ESBL producers. 
x Among the colonizers Pseudomonas aeruginosa was the  commonest (10%) 
followed by Proteus mirabilis in 7% 
x No significant antibiotic resistance was observed among the colonisers. 
x Anaerobes were presumptively identified in 14% of the ulcers using 
anaerobic antibiotic identification disks. Peptostreptococcus anaerobicus 
was isolated from 12% of the ulcers and Bacteriodes fragilis from 2 % .                           
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CONCLUSION 
x Venous  leg ulcers  are  predominant  in the age group 61-70.  
x The commonest pathology associated with venous ulcers is perforator 
incompetence. 
x Significant  risk factors associated were DVT ,Obesity  and  varicose veins . 
x The diagnosis of infection can be done by quantitative culture method using 
tissue biopsy. The ulcers are  monomicrobial or polymicrobial. 
x Rate of infection in venous ulcers is 48%. 
x Staphylococcus aureus is the most common pathogen followed by members 
of Escherichia coli. 
x MRSA is a significant pathogen in the etiology of venous leg ulcers , 
majority of which were also found to be  moderate  biofilm producers. 
x Among the Enterobacteriaceae  family ,ESBL production is a cause of  
antimicrobial resistance  though no  AmpC  or MBL producers were detected  
in this study. 
x Anaerobes  constitute a significant proportion of the etiological agents of the 
venous  leg ulcer patients. 
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The presence of infection and non infection in the wounds  should be 
determined for treatment purposes.As there is debate whether to treat the colonized 
wound Direct microscopy  and quantitative microbiological culture which detects 
the presence of bacteria greater than 105 CFU/gram tissue  can be an useful guide to 
initiate treatment of the venous leg ulcers.                                            
 
 
                                        FIGURE 2: VENOUS LEG ULCER 
 
 
 
FIGURE 3: PROCESSING OF TISSUE  
 
           
 
 
 
FIGURE 4: DIRECT GRAM STAIN SHOWING GRAM POSITIVE COCCI 
IN CLUSTERS 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5: QUANTITATIVE CULTURE OF TISSUE 
 
 
FIGURE 6: ANTIBIOGRAM OF MRSA ISOLATE SHOWING CEFOXITIN 
RESISTANCE 
 
 
FIGURE 7: TUBE COAGULASE TEST 
 
 
 
 
FIGURE 8: DETERMINATION OF MIC FOR VANCOMYCIN FOR MRSA  
ISOLATES BY MACRO BROTH DILUTION METHOD  
 
 
FIGURE 9: STREPTOCOCCUS PYOGENES SHOWING BACITRACIN 
SENSITIVITY 
   
 
FIGURE 10: PHENOTYPIC CONFIRMATION DISC DIFFUSION TEST 
(PCDDT) FOR ESBL PRODUCTION 
 
 
FIGURE 11: IDENTIFICATION OF ANAEROBES USING DIFFERNTIAL 
DISKS 
 
FIGURE 12: GRAM STAIN FROM ANAEROBIC CULTURE SHOWING 
GRAM POSITIVE COCCI IN PAIRS AND SHORT CHAINS  
 
 
 
FIGURE 13: BIOFILM FORMATION BY MRSA ISOLATES  
 
 
APPENDIX I 
ABBREVATIONS 
CVI    CHRONIC VENOUS INSUFFICIENCY 
CVD    CHRONIC VENOUS DISEASE 
VLU       VENOUS LEG ULCER 
ESBL                        EXTENDED BROAD SPECTRUM BETA LACTAMASE 
MRSA                      METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
MSSA                       METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS  
MBL                         METALLOBETA LACTAMASE 
AVF                          AMERICAN VENOUS FORUM 
CEAP                        CLINICAL -ETIOLOGY- ANATOMY- PATHOLOGY 
VSS                VENOUS SEVERITY SCORE 
CFU                          COLONY FORMING UNIT 
IP                              IN PATIENT 
OP                            OUT PATIENT 
MIC              MINIMUM INHIBITORY CONCENTRATION 
CLSI                         CENTRAL LABORATORY STANDARD INSTITUTE 
BSAC                       BRITISH SOCIETY OF ANTIBIOTIC CHEMOTHERAPY 
VSI                           VASCULAR SOCIETY OF INDIA 
VAI                          VENOUS ASSOCIATION OF INDIA 
DVT                         DEEP VEIN THROMBOSIS 
GSV                         GREAT SAPHENOUS VEIN 
SSV                          SHORT SAPHENOUS VEIN 
IVC    INFERIOR VENACAVA 
VEGF   VASCULAR ENDOTHELIAL GROWTH FACTOR 
TGF                          TRANSFORMING GROWTH FACTOR 
MMP   MATRIX METALLOPROTEINASES 
EMMPRIN  EXTRACELLULAR MMP INDUCER 
VCSS   VENOUS CLINICAL SEVERITY SCORE 
VSDS  VENOUS SEGMENTAL DISEASE SCORE 
VDS    VENOUS DISABILITY SCORE 
ABPI                        ANKLE BRACHIAL PRESSURE INDEX 
TBPI                         TOE BRACHIAL PRESSURE INDEX 
ATCC                       AMERICAN TYPE CULTURE COLLECTION  
MR                            METHYL RED 
VP    VOGES PROSKAUER 
CM    CENTI METERS 
MM   MILLI METERS 
GM    GRAMS 
  
APPENDIX II 
A. STAINS AND REAGENTS 
1. Gram staining 
Methyl violet (2%)   l0g Methyl violet in 100ml absolute alcohol  
in 1 litre of distilled water (primary stain) 
Grams Iodine    l0g Iodine in 20g KI (fixative) 
Acetone    Decolourising agent 
Carbol fuchsin 1%   Secondary stain. 
B. MEDIA USED 
Mac Conkey agar 
Peptone     20g 
Sodium taurocholate   5g 
Distilled Water    1 ltr 
Agar       20 g 
2% neutral red in 50% ethanol  3.5ml 
10% lactose solution   l00ml 
Dissolve peptone and taurocholate in water by heating. Add agar and dissolve 
it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix. 
Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes. 
2. Nutrient agar 
Peptic digest of animal tissue  5g 
Sodium chloride    5g 
Beef extract     1.5g 
Yeast extract     1.5g 
Agar       15gm 
Final pH 7.4±0.2 
Suspend 28 grams in 1000 ml distilled water. Heat to boiling to dissolve the 
medium completely and sterilized by autoclaving at 15 lbs pressure (120°C) for 15 
minutes. 
3. Blood agar (5% sheep blood agar) 
Peptone l0g 
NaCl 5g 
Distilled water 1 Ltr 
Agar l0g 
Dissolve   ingredients   in   distilled   water   by   boiling,   and  add  5%  sheep 
blood (sterile) at 55°C adjust pH to 7.4. 
4. Chocolate agar 
Sterile defibrinated blood 10 ml 
Nutrient Agar (melted) 100 ml 
When the temperature was about 75°C, sterile blood was added with constant 
agitation. After addition of blood, kept in water bath and heating was continued till 
the blood changed to chocolate colour. Cooled to about 50° C and poured about 15ml 
into petri dishes with sterile precaution. 
5. Cation adjusted Mueller- Hinton Agar 
Beef infusion     300ml 
Caesein hydrolysate    17.5g 
Starch      1.5g 
Agar       l0g 
Distilled water    1 ltr 
pH = 7.4 
Sterilise by autoclaving at 121°C for 20 mins 
6. Robertson's Cooked Meat Broth 
Fresh bullock heart    500g 
Water      500ml 
Sodium hydroxide, mol /Lit  1.5ml 
Liquid filtered from cooked meat  500ml 
Peptone     2.5g 
NaCl       1.25g 
7. Selective Anaerobic Blood Agar: 
1 µg/ml menadione and 20 µg/ml gentamicin added to the blood agar. 
8. Thioglycollate broth 
Pancreatic digest of casein 15gms 
Yeast extract 5gms 
Dextrose (Glucose) 5.5gms 
Sodium chloride 2.5gms 
L-Cystine 0.5gms 
Autoclaved at 15 lbs pressure (121°C) for 20 minutes. 
Note: If more than the upper one-third of the medium has acquired a pink 
colour, the medium may be restored once by heating in a water bath or until the 
pink colour disappears. 
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
1. Oxidase Reagent 
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
2. Catalase 
3% hydrogen peroxide 
3. Coagulase test 
Tube coagulase test 
1. Prepare a 1 in 6 dilution of the plasma in saline and place 1 ml volume of the 
diluted plasma in small tube. 
2. Emulsify a colony of the Staphylococcus under test in the tube of the diluted 
plasma 
3. Appropriate controls were put up 
4. Incubate the tubes at 37°Cfor 4 hours 
5. Examine the tubes at 1,2,3 4 hours for Clot formation 
6. Leave the tubes at room temperature overnight and reexamine  
7. Read as positive any degree of clot formation 
Slide Coagulase test 
Emulsify a staphylococcus colony in a drop of water on a microscope slide 
with a minimum of spreading .Make a similar suspensions of control positive and 
negative strains to confirm the proper reactivity of the plasma. Stir the adhering 
plasma into Staphylococcal suspension on the slide. Formation of Clumps are read 
as Positive. 
4. Indole test 
Kovac's reagent 
Amyl or isoamyl alcohol 150ml Para dimethyl amino benzaldehyde – l0g 
Concentrated hydrochloric acid - 50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
5.Christensen's Urease test medium 
Peptone lg 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 2g 
Phenol red 6ml 
Agar 20g 
Distilled water 1 ltr 
10% sterile solution of glucose 10ml 
Sterile 20% urea solution   100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving 
in a flask at 121°C for 30min. Cool to about 50°C, add the glucose & urea, and tube 
the medium as slopes. 
 
 
6. Simmon's Citrate Medium 
Koser's medium    1 ltr 
Agar       20 g 
Bromothymol blue 0.2%   40ml 
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
7. Triple Sugar Iron medium  
Beef extract         3g 
Yeast extract         3g 
Peptone         20g 
Glucose         lg 
Lactose         10 g 
Sucrose         l0g 
Ferric citrate         0.3g 
Sodium chloride         5g 
Sodum thiosulphate         0.3g 
Agar         12g 
Phenol red 0.2% solution          12ml 
Distilled water         1 ltr 
Heat to dissolve the solids, add the indicator solution, mix and tube. 
Sterilize at 121°C for 15 min and cool to form slopes with deep butts. 
 
 
8. Glucose phosphate broth  
Peptone        5g 
Dipotassium hydrogen phosphate       5g 
Water       1 ltr 
Glucose 10% solution        50ml 
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense 
in 5ml amounts and sterilize at 121°C for 15min. Sterilize the glucose solution by 
filtration and add 0.25ml to each tube. 
Methyl Red Reagent  
Methyl Red l0mg 
Ethyl alcohol 30ml 
Distilled water 20ml 
VogesProskauer Reagent  
Reagent A: Alpha naphthol 5g 
Ethyl alcohol 100ml 
Reagent B: Potassium hydroxide 40g 
Distilled water 100ml 
9. Peptone water fermentation test medium 
To  the  basal  medium  of  peptone  water,  add  sterilised  sugars  of  1%  
indicator bromothymol blue with Durham's tube. Basal medium peptone water 
Sugar solutions: 
Sugar       1ml 
Dislilled water    100ml    pH = 7.6. 
10.Mannitol motility medium  
Agar             5g 
Peptone lg 
Potassium nitrate             1g 
Mannitol             2g 
Phenol red indicator  
Distilled water 1000ml 
pH               7.2 
12. Potassium nitrate broth  
Potassium nitrate (KNO3) 0.2gm 
Peptone               5.0gm 
Distilled water  100ml 
The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclaved. 
13. Phenyl alanine deaminase test  
Yeast Extract 3g 
Dl-Phenylalamine 2 g 
Disodium hydrogen phosphate l g 
Sodium Chloride 5 g 
Agar 12g 
Distilled water 1 lr 
PH 7.4 
Distributed in tubes and sterilized by autoclaving at 121° C for 1 5 minutes, 
allowed to solidify as long slopes. 
14. Sugar fermentation medium  
Peptone 15g 
Andrade's indicator 10 ml 
Sugar to be tested 20g 
Water 1 litre 
Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to which sufficient 
1M sodium hydroxide has been added to turn the colour of the solution yellow. 
Dissolve the peptone and Andrade's indicator in 1 litre of water and add 20g 
of the sugar; sugars to be tested generally include glucose, sucrose, lactose and 
maltose. Distribute 3ml amounts in standard test tubes containing an inverted 
Durham tube. Sterilize by steaming at 100 degree C for 30 min on 3 consecutive 
days. 
 
 
 
 
                                             
  
APPENDIX    III 
Panel of antibiotic Disk used for Staphylococcus aureus and Coagulase negative 
Staphylococcus (Hi Media) 
ANTIBIOTIC 
DISK 
CONENT SENSITIVE 
(mm) 
INTERMEDIATE 
(mm) 
RESISTANT 
(mm) 
Penicillin 10 units 29 - 28 
Cefoxitin 30µg 22(For 
S.aureus and 
S.lugdenesis) 
- 21 
 CoNS 25 - 24 
Gentamicin 10µg 15 13-14 12 
Amikacin 30µg 17 15-16 14 
Tetracycline 30µg 19 15-18 14 
Ciprofloxacin 5µg 21 16-20 15 
Erythromycin 15µg 18 14-17 13 
Clindamycin 2µg 21 15-20 14 
Trimethoprim-
Sulfamethoxazole 
1.25/23.75µg 16 11-15 10 
Linezolid 30µg 21 - 20 
 
  
Panel of drugs used for Enterococcus spp 
Antibiotics Contents Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Pencillin 10 units 15 - 14 
 
Vancomycin 30µg 17 15-16 14 
Tetracycline 30 19 15-18 14 
Erythromycin 15µg 23 14-22 13 
Ciprofloxacin 5µg 21 16-20 15 
High level 
gentamicin 
120µg 10 7-9 6 
Chloramphenicol 30µg 18 13-17 12 
 
Panel of drugs used for ȕ Hemolytic streptococcus spp 
Antibiotic Content Sensitive(mm) Intermediate(mm) Resistant(mm) 
Pencillin 10 units 24 - - 
Cefotaxime 30µg 24 - - 
Vancomycin 30µg 17 - - 
Erythromycin 15 µg 21 16-20 15 
Tetracycline 30 µg 23 19-22 18 
Ofloxacin 5 µg 16 13-15 12 
Clindamycin 2 µg 19 16-18 15 
 
 
Panel of drugs used for Diphtheroids (According to BSAC Guidelines) 
Antibiotic Content Sensitive(mm) Intermediate(mm) resistant(mm) 
Penicillin 10  µg 20  19 
Ciprofloxicin 5  µg 17 12-16 11 
Vancomycin 30 µg 20  19 
 
Panel of drugs used for Enterobacteriaceae 
Antibiotic Content Sensitive(mm) Intermediate(mm) resistant 
(mm) 
Cefotaxime 30 µg 26 23-25 22 
Ceftazidime 30 µg 21 18-20 17 
Gentamicin 10 µg 15 13-14 12 
Amikacin 30 µg 17 15-16 14 
Tetracycline 30 µg 15 12-14 11 
Ciprofloxacin 5 µg 21 16-20 15 
Trimethoprim-
Sulfamethoxazole 
1.25/23.75 
µg 
16 11-15 10 
Chloramphenicol 30 µg 18 13-17 12 
Imipenam 10 µg 23 20-22 19 
Cefoxitin 30 µg 18 15-17 14 
Piperacillin-
tazobactam 
100/10 µg 21 18-20 17 
 
Panel of drugs used for Pseudomonas aeruginosa 
Antibiotic Disk 
Content 
Sensitive(mm) Intermediate(mm) Resistant(mm) 
Piperacillin-
tazobactam 
100/10 µg 21 15-20 14 
Ceftazidime 30µg 18 15-17 14 
Imipenam 10µg 19 16-18 15 
Amikacin 30µg 17 15-16 14 
Ciprofloxacin 5µg 21 16-20 15 
Gentamicin 10µg 15 13-14 12 
 
Panel of drugs used for Acinetobacter spp 
Antibiotic Disk 
Content 
Sensitive 
(mm) 
Intermediate 
(mm) 
Resistant 
(mm) 
Piperacillin-
tazobactam 
100/10 
µg 
21 15-20 14 
Ceftazidime 30µg 18 15-17 14 
Cefotaxime 30µg 23 15-22 14 
Imepenam 10µg 22 19-21 18 
Gentamicin 10µg 15 13-14 12 
Amikacin 30µg 17 15-16 14 
Tetracycline 30µg 15 12-14 11 
Ciprofloxacin 5µg 21 16-20 15 
Trimethoprim-
Sulfamethoxazole 
1.25/23.7
5 µg 
16 11-15 10 
ANNEXURE 1  
CERTIFICTE OF APPROVAL 
 
ANNEXURE –II 
PROFORMA 
 
x Name :                                                                       OP NO/IP NO: 
x Age:                                                                           Ward: 
x Sex: 
x Occupation: 
x Address: 
 
Presenting complaints: 
Site of the Ulcer: 
Duration of Ulcer: 
Past history:  
 
Personal history: 
• Alcohol intake: 
• Cigarette smoking: 
 
Associated factors: 
• Pregnancy 
• Known tuberculosis patient /HIV 
• Chronic steroid intake 
• Diabetes mellitus 
• Lymphoma /Leukemia /Malignancy/on Chemotherapy 
• Previous Surgeries: 
• Hypertension 
• Any Other Abdominal Tumours 
•General examination: 
Built: 
Weight: 
Nourishment: 
BP: 
Temperature: 
CVS: 
RS: 
Abdomen: 
 
 Local examination 
 
Any Visible Varicose Veins: 
Skin changes: 
Site of Ulcer 
Signs of Inflammation 
Redness: 
 
Odour:      
 
Cellulitis: 
 
 
Provisional diagnosis: 
Laboratory evaluation: 
Biochemical parameters: 
y Plasma glucose levels 
y  Blood urea 
y Creatinine 
  
Hematological investigations: 
x TC 
x DC 
x Hb estimation 
x ESR 
Doppler study : 
 
Microbiological investigation: 
Sample collected: 
x Tissue bits from the Ulcer 
Direct examination: 
x Gram’stain: 
Bacterial Culture: Tissue 
Aerobic: 
y MAC 
y BAP 
Anaerobic 
o BAP 
o CAP          
 
  Colony Count              
 
Antibacterial susceptibility pattern: 
 
 
 
ANNEXURE III 
INFORMATION SHEET 
 
STUDY TITLE: “A study on secondary bacterial infections in patients with 
venous leg ulcer and their antimicrobial susceptibility pattern in a Tertiary 
care Hospital” 
 
 
Venous leg ulcer (stasis ulcers, varicose ulcers) is a severe clinical 
manifestation of chronic venous insufficiency (CVI).  The healing of venous ulcers 
is a complex process, which requires a multifaceted approach, including 
compression, debridement, and control of bacterial overgrowth. Bacterial 
colonization and the growth of bacteria on Venous Ulcers  occurs since it is a moist 
surface . Microbial infection delays the healing of the Venous Ulcer and 
Complicates the Treatment. These Microorganisms develop anti-microbial 
resistance and are difficult to treat with antimicrobial agents. I am going to evaluate 
the organism infecting the Venous Ulcer and determine the antibiotic susceptibility 
pattern. I am going to collect Pus samples and Tissue samples from patients who 
have Venous Ulcer and process them accordingly.100 patients are included in this 
study after getting informed consent only. This study is entirely voluntary and 
patient can withdraw any time from this study. Extra cost will not be incurred to the 
patients in this study. Any doubt regarding this study will be willingly clarified. 
Results of the study will be published. In case of any doubt.  
 
Signature of investigator                                                Signature of Participant 
Date: 
  
PATIENT CONSENT FORM 
 
TITLE OF THE STUDY :“A  study on secondary bacterial infections in 
patients with venous leg ulcer and their antimicrobial susceptibility 
pattern in a Tertiary care Hospital” 
 
Name :        Date  : 
Age :        OP No  :  
Sex :        Project Patient No: 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been 
read to me). I was free to ask any questions and they have been answered. I  hereby give 
my consent to be included as a participant in “A  study on secondary bacterial infections 
in patients with venous leg ulcer and their antimicrobial susceptibility pattern in a 
Tertiary care Hospital’’ 
I have read and understood this consent form and the information provided to me. 
1. I have had the consent document explained to me. 
2. I have been explained about the nature of the study. 
3. I have been explained about my rights and responsibilities by the investigator.  
4. I have been informed the investigator of all the treatments I am taking or have taken in 
the past ________ months including any native (alternative) treatment. 
5. I have been advised about the risks associated with my participation in this study. 
6. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms. 
7. I have not participated in any research study within the past ________ month(s). 
8. I am aware of the fact that I can opt out of the study at any time without having to give 
my reason and this will not affect my future treatment in this hospital. 
9. I am also aware that the investigator may terminate my participation in the study at any 
time, for any reason, without any consent. 
10. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
11. I have understand that my identity will be kept confidential if my data are publicly 
presented. 
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
For  participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant  incompetent/For age 10-17 yrs-Name& signature of the parent/guardian.) 
 
Name ___________________________________ 
Signature_________________________  
Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name ___________________________________ 
Signature_________________________  
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name ___________________________________ 
Signature_________________________  
Date_______________ 
OP NO/IPNO AGE SEX OCCUPATION MAIN C/O
DURATION 
OF ULCER SIDE SITE OF ULCER DM/HT/COMORBIDsurgery for varicose veins ALCOHOLIC/SMOKER VISIBLE VARICOSE VEINSINVESTIGATIONS-DOPPLER OTHER INVESTIGATIONS
IP no 11725 50 M Cycle Token worker pain 10 years Rt above Rt medial malleolus DM OPERATED FOR VARICOSE VEINS  3 TIMES ALCOHOLIC/SMOKER NIL Rt-SFV junction incompetence grade I TC-7200,DC-P70,L-30 HB-14.1,ESR-2/8,RBS-116
op no:1314277 65 M Security worker pain 8 years Lt above 2cms Lt-Medial malleolus DM ALCOHOLIC YES Lt SFV junction incompetence grade II TC-7260,DC-P-65,L-32,E-3, HB-15.2,ESR-4/8,F-206,PP-300,Bl urea-32,Creatinine-0.8
op no:26456 53 M Security worker pain 8years Lt Lt-Above lateral Malleolus OPERATED FOR Haemorrhoidectomy 10 years,Total Hip replacement 6 years,DVT-2yrs,TB treated- 11/2 years backNIL YES Lt-Parti l DVT of Popliteal, Post Tibial veins with dilatation of SFV junctionTC-5800,DC-P70,L-28,E-2,Hb-15.2,ESR-4/8,RBS-86 urea-30,creatinine-0.9
op no:11950 48 M Vegetable vendor discharge 10 years Rt Below  Rt Lateral Malleolus DM Alcoholic YES Rt-SFV junction incompetence grade II TC-14000,DC P-90,L6,E4,HB-14.4,ESR-40/80
ip no 141322 47 M Cook swelling 2 years Lt Lt-Above medial Malleolus NIL ALCOHOLIC/SMOKER B/L VaricoseveinsB/L sapheno femoral junction incompetence Grade I TC-9000,DC P-70,L-30 HB-14.1,ESR-2/8
opno:VS-1235/15 70 M Security worker pain 10 years Rt above Rt medial malleolus NIL Operated two times for varicose veins ALCOHOLIC/SMOKER YES Rt-SFV junction incompetence grade II TC-5400,DC-P50,L-45,E-5,Hb-13.8,ESR-6/8,RBS-98, BU-28,CREATININE-0.9
op no:632/15 65 M Security worker pain 8 years Lt Above Lt medial malleolus DM/HT NIL YES Lt-SFV junction incompetence grade II TC-7800;DC-P60,L-38,E 2;HB-14.8,ESR 4/8 RBS-160, BI UREA 6 CREATITINE 1.2
op no 6275 62 M COOK pain 10 years Lt ABOVE LT ANKLE-lateral malleolus DM OPERATEDFOR VARICOSE VEINS 2 YEARS NIL NIL Lt-sfv junction incompetence grade I,below knee perforator incompetenceTC-11OOO,DC-P74,L26,HB-6.7,ESR 70,RBS -273,UREA 36,CREATININE1.2
op no 67081 48 M Electrician pain 4 years Lt Lt-Above medial Malleolus NIL NIL NIL Lt SFV junction incompetence grade I,B/Knee,15 cms above ankle perforator incompetenceTC-7200,DC-P42,L-56,E-2 HB-15.7,ESR-2/8,RBS-108, UREA 26,CREATININE1.0
opno:VS-1962/13 60 M Tea stall owner pain 5 years Rt 2 cms above Rt Medial malleolus OBESE ALCOHOLIC YES Rt-sfv junction incompetence grade II TC- -7200,DC-P60,L9,E1,HB-16.2
ip no 7826/wd 30s 60 M Tea stall owner swelling 7 YEARS Rt above Rt medial malleolus NIL ALCOHOLIC/SMOKER YES RT-SFV JUNCTION INCOPETENCE ,NO EVIDENCE OF THROMBOSIS IN COMMON FEMORAL VEIN AND SAPHENOUS VEINTC-13900,DC-P76,L16,M7, 1,HB-9.2,ESR 70,RB -118,BLOOD UREA 45 CREATININE -0.8
op no:2611/14 35 M Hotel server pain 5years Lt Above Lt medial malleolus OBESE ALCOHOLIC/SMOKER NIL Lt- Knee perforator incompetence TC-5200;DC-P-68,L-28,E-6,HB-15.2,ESR 2/8 RBS-98,BLOOD UREA-32,CREATININE 0.8
op no 8272/14 45 M Farmer discharge 8 years Lt above Lt medial malleolus extending to lateral ascept 8 x8 cmsNIL operated for Varicose Veins 2 years back ALCOHOLIC NIL POSTPHLEBHOTOMY STATUS LT KNEE PERFORATOR INCOMPETENCE
op no :872/14 38 M Tailor pain 5 years Rt GAITER REGION NIL Skin grafting done -2 yrs back ,Previous DVT  2 years backNIL NIL Rt-SFJ incompetence Grade I TC-8200,DC-P-72,L-26,E-2,HB-13.2 GMS,ESR-20/40
op no 7562 60 F house wife Pain/discharge 6 years Lt Lt-Above medial Malleolus HT/CVA R NIL NIL Lt-SFV junction incompetence TC-4500,DC-P70,L29,E-1,HB-7.2 GRAMS,ESR-70
op no:636/13 67 M iron man discharge 7 years Rt Rt-above medial malleolus NIL NIL YES,DILATEDRt-SFJ incompetence Grade III TC-5200;DC-P-56,L-32,E-6,HB-13.2,ESR 8/16 RBS-120,BLOOD UREA-27.7,CREATININE 1.0
op no;185659 45 M Barber Pain 8 years Lt Rt-below ankle joint NIL ALCOHOLIC NIL Lt-SFV INCOMPETENCE GRADE I TC-7800;DC-P68,L-26,E 6;HB-15.8,ESR 4/8 RBS-92, BI UREA286 CREATITINE 0.8
op no;889/13 47 M Autodriver swelling 5 years Rt Below  Rt  knee and above Rt-medial malleolus NIL ALCOHOLIC yes Rt-SFV Incompetence  above knee and below knee perforator incompetenceTC-9200,DC P-68,L-28,E-4 HB-16.2,ESR-6/10 RBS-120,UREA-22 CREATININE-1.0
op no:363/14 40 M worker in plastic company Pain 6months Rt Rt-above medial malleolus HERNIORRHAPHY -8 MONTHS BACK,OBESE ALCOHOLIC/SMOKER YES Rt-SVJ Incompetence TC-5600,DC-P-70,L-0,HB-15.0GMS,ESR2/8,RBS-128 UREA-30,CREATININE0.8
op no:37236 35 M Gardener pain 8 years Lt Lt-Above medial Malleolus DM ALCOHOLIC Echogenous thrombosis noted ext CFV upto Popliteal vein occluding 60% of vessels artially recanalised DVTTC-9800,DC-P-76,L24,HB-12.8 GMS,ESR-12/18,RBS108,UREA-36,CR-1.1,
op no:12900 39 M Factory worker Pain 8 years Rt Rt-above medial malleolus HT ALCOHOLIC/SMOKER yes Rt-SFV Incompetence  TC-8200 DC-P 64 L6,HB-15.2 ESR 2/8 RBS 128
op no:46879 66 M watchman Pain 5 years Rt Rt-above medial malleolus ALCOHOLIC/SMOKER YES B/L sapheno femoral junction incompetence Grade II TC-5400,DC-P54,L-36,E-8,M-2,Hb-13.2,ESR-2/8,RBS-98, BU-32,CREATININE-0.8
op no:44954 65 F house wife Pain/discharge 8 years Rt Rt-above medial malleolus DM/DVT -3 years back YES B/L BK,AK,PERFORATORINCOMPETENCE TC-7500,DC-P72,L28,HB-9.2 ,ESR 16/2,RBS -220 UREA-36 CR-1.2
opno:370074 67 M Farmer Pain/discharge 10 years Lt On lateral malleolus near ankle joint NIL Nil ALCOHOLIC/SMOKER NIL B/L BK,AK,PERFORATOR INCOMPETENCE LT SIDE TC-7200,DC-P72,L28,HB-15.2 ,ESR 2/8 RBS 108 UREA-30 CR-0.8
op no:4090/09 56 M watchman Pain 5 yeasr Rt Rt-above medial malleolus NIL ALCOHOLIC/SMOKER NIL Rt-SFV junction incompetence gradeII TC-5500,DC P-64,L-36,ESR 4/8,HB-12.2 ,RBS 122 UR-30,CR-0.8
op no.715/94 68 M watchman Pain/discharge 20 years Lt Lt lateral malleolus DM NIL ALCOHOLIC/SMOKER Yes Lt-SFV junction incompetence Grade II TC- , 7800, DC-P54, L-36, E-8. HB-15.2,ESR-2/8 RBS-180, Urea-32,CR-1.1
op no2556/09 65 M Security worker Pain 5years Rt Rt-above medial malleolus NIL SMOKER nil Rt-SFJ incompetence TC-6200,DC P-68,L 32 HB-14.1,ESR 2/8 RBS -90 UR-30 CR-0.8
op no 256/15 45 F house wife Pain 6 years Rt>lt Rt-above medial malleolus NIL Nil NIL YES B/L SVJUNCTION INCOMPETENCE GRADE I RT-BELOW  KNEE PERFORATOR I/CTC-8000,DC P70,L0,HB-10.2 ESR-8/16,R 98, UR-, CR-0.9
op no127/15 68 M Aavin worker (Retd) Pain/discharge 15 years Lt Lt-Above medial Malleolus NIL SMOKER NIL Lt-sfv junction incompetence grade III TC-7800,DC P-62,L37,E-1,HB-15.2, ESR 2/8,RBS 98,UR-30,CR-0.8
op no: 165/09 38 M Coolie Pain/discharge 6 years Rt lateral malleolus DM NIL NIL Rt-SFJ I/C AK ,BK,PERFORATOR I/C LT-SFV JUNCTION COMPETENTTC-10000,DC-P-80,L-20,HB-10.2,ESR-16/32,RBS 150,UR-30,CR-1.0
op ni : 29/2015 49 M iron man pain 10 years Lt Multiple ulcer Lt- side of leg dorsal ascept NIL Nil NIL NIL Lt-SFJ INCOMPETENCE GRADE II TC-4800,DC-P-64,L32,E4 HB-15.2,ESR -8/16,RBS-98,UR-22,CR-0.8
op no: 335/15 38 M coolie discharge 10 years Lt Lt-Above medial Malleolus Alcoholic NIL Lt-SFV junction incompetence with grade i TC-7200, DC-P-70,L-26,E-4,HB -14.2,ESR-2/8,RBS 92,UR-24,CR-0.8
op no;2382/04 25 M Centering Coolie Cellulitis 5 years lt Lt-Above medial Malleolus Alcoholic yes Lt-SFV junction I/C grade I TC-4200,DC-P 72,L26,E-,HB-15.2,ESR 2/8,RBS-92,UR-19,CR-1.0
op no:4425/08 55 F house wife pain 10 years Rt Rt-above medial malleolus NIL Nil NIL YES Rt-SVJ Incompetence grade I TC-6200,DC P-60,L 36,E-4 HB-9.2,ESR 8/16, RBS -112, UR-20 CR-0.8
op no 53552 75 M coolie discharge 15 years Rt Rt-above medial malleolus DM ALCOHOLIC/SMOKER YES B/L SUPERFICIAL VEINS DILATATION ,BK,PERFORATOR I/C TC-8800,DC-P-60,L-36,E-4,HB-12.2,ESR-18/32,RBS-90,UR-22,CR-0.8
op no : 85/2015 61 M Security worker pain 2 years Rt Rt-above medial malleolus HT NIL YES Rt-BK PERFORATOR I/C TC-6200,DC P-70,L0 HB-12.2 ESR 8/16, RBS-120,UR-30,CR-0.8
op no :41456 55 F house wife pain 10 years Rt GAITER REGION NIL YES AK,BK, PERFORATOR I/C TC-5600,DC-P-54,L-38,E-8,HB-12.2GMS,ESR2/8,RBS-128 UREA-20,CREATININE0.8
op no:9235 59 F bhajji shop owner Pain/discharge 10 years Rt Rt -above medial malleolus NIL yes Rt-SFV junction I/C Grade II TC-5800,DC-P72,L-28,E-2,Hb-12.2,ESR-8/16,RBS-120 urea-20,creatinine-0.8
op no:1805110 65 F construction worker pain/discharge 10 years RT Rt-above medial malleolus NIL YES Normal arterial study Normal venous flow OF Lt-LL,Rt-AA,BK PERFORATOR I/CTC-5200,DC-P-62,L-36,E-2,HB-9.8 ESR20/40,RBS 90,UR-25,CR-0.6
op no:1186110 43 M supervisor in a market pain 5 years Rt Rt-above medial malleolus Recurrent attacks of DVT,Foam sceloro therapy done -3 yearsALCOHOLIC/SMOKER NIL Rt-SFJ AND PERFORATOR I/C TC-5200, DC P-70,L-30,ESR 2/8,HB 14.2, RBS 90, UR-15,CR-0.6
op no:58020 70 M coolie pain/swelling 15 years Rt Rt-above lateral malleolus SHT RTA-20 years back, Plating done for R femur,Haemorrhoidectomy done -5 yearsAlcoh lic Yes Normal venous flowboth sides Rt-BK PERFORATOR I/C TC-9700,DC-P72,L 26,HB-10.2,ESR 20/40,RBS-120,UR-28,CR-0.6
0p no:415/2015 43 M watchman pain and odour 3 years Rt> Lt B/L MEDIAL MALLEOLUS ULCERS DM SMOKER YES B/L SVJUNCTION INCOMPETENCE GRADE I B/L-BELOW  KNEE PERFORATOR I/CTC-8600,UR-18,CR-0.6,DC-P45,L-45,E-10,RBS-88,HB-12.1 ESR 2/8
opno:172895 43 M farmer pain and discharge15 years Rt Rt-above medial malleolus operated  years back for varicose veins Alcoholic YES Recanalised GSV,Dilated CFV/Popliteal Vein TC-10200,DC-P-70,L-28,E-2,HB-14.2,ESR-2/8,RBS 98,UR-26,CR-1.0
op no :85324 65 F household worker pain 5 years Lt Lt-Above medial Malleolus OBESE YES B/L,SFV JUNCTION I/C TC-7800,DC P-68,L26,E-6,HB-10.2, ESR 2/8,RBS-118,UR-26,CR-0.6
opno:7659 63 F cook Pain 5 years Rt Rt-above medial malleolus NIL B/L AK,BK perforator I/C TC-5400,DC-P72,L-28,HB-12.2,ESR 2/8,RBS-108,UR-26,CR-0.6
op no 838/12 47 M Mechanic pain/discharge 10 years Lt Lt-Above medial Malleolus SMOKER YES Dilated SFV Junction I/C AK,BK,PERFORATOR I/C-LT TC-9200,DC P-54,L-38,E-8 HB-16.2,ESR-4/8 RBS-98,UREA-20 CREATININE-0.6
OP NO 865/09 52 M Farmer PAIN 15 YEARS Rt Rt-above medial malleolus ALCOHOLIC NIL B/L SFV JUNCTION I/C,BK,B/L PERFORATOR I/C TC-5200,DC-P-64,L-36,,HB-15.8 ESR4/8,RBS -120,UR-16,CR-0.6
op no: 353/12 70 M coolie discharge 14 years Lt Behind Lt- medial malleolus ALCOHOLIC/SMOKER NIL B/L SFV JUNCTION I/C, TC-5600,DC-P-70,L-30,ESR2/8,HB-16.2 ,RBS-102,UR-20,CR-0.6
op no:1039/12 51 M Mason discharge 4 months Lt Lt-Above medial Malleolus yes B/L BK perforator I/C TC-6200,DC-P68,L-26,E-6,HB-10.2,ESR4/8,RBS-118,UR-22,CR-0.6
op no 792/09 53 M Mechanic pain 5 years Lt Lt-Above medial Malleolus OBESE ALCOHOLIC/SMOKER YES LT-BK AA PERFORATORS I/C TC-7200,DC-P-62,L-28,E-10,ESR-22/50,HB-10.2,RBS-98,UR-22,CR-0.9
op no: 14856 28 M Autodriver Pain/Discharge 5 years Rt Rt-medial malleolus extending to lateral malleolus OBESE Operated for perforators -2 years Alcoholic yes Rt-SFV incompetence gradeII TC-5200,P56,L-34,M-2,HB-15.2,ESR 2/8 ,RBS-94,UR-24,CR-0.8
op no:2060/12 42 F Tailor Pain 12 years Rt Multiple ulcer above Rt medial malleolus Known case of RHD -MVR _20 years yes Rt-SFV incompetence gradeII,Below knee perforator incompetenceTC-6200,P-68,L-32 HB-10.2,ESR 10/24 ,RBS-82,UR-18,CR-0.8
op no:536/6 38 F Tailor Pain 2 years Rt Rt-medial malleolus  above yes TC-6600,DC-P-54,L-44,E -2,HB-10.2 ESR-8/16,RBS-80,UR-20,CR-0.8
op no:28042 59 M Security worker Pain/Discharge 7 years Lt Above medial malleolus multiple Dm Operated 2 years SSG done Alcoholic nil Lt-perforators incompetence Rt-LL SFJ incompetence grade II TC-7200,DC-P68,L-32,HB-12 GR,UR-30,ESR-20/40,CR-0.8,
op no:28081 30 M Tailor Pain 2 years Lt Lt-Above medial malleolus Operated  for B/L varicose veins 7 years back Alcoholic/smoker Rt-LL dilated veinsRt-SFJ incompetence TC-7200,DC-P56,L-38,E-6 HB-14 GR,UR-20,ESR-8/16,CR-0.8,
op no: 2354/14 60 M Coolie Pain/Discharge 15 years Rt Lt-lateral malleolus Alcoholic/smoker nil I/Cperforators at bB/A,BK,AK ,B/L grade ISF junction incompetenceTC-7200,DC-P76,L-26,Hb-15.1 GMs,ESR-4/8 ,RBS 82,UR-20,CR -0.8
op no: 26175 60 M Autodriver pain 15 years Rt Rt-above medial malleolus Known case of RHD B/L varicose veins  with Lt ulcer yes B/L GSV grade I Incompetence, Perforator incompetence B/L BK,AA, PerforatorsTC-5400,DCP-72,L 26 HB-15.1 GMS,ESR 10/24,RBS -140,UR-22,CR-0.8,
op no: 668/2015 60 M Farmer Pain/Discharge 15 years Lt Rt-medial malleolus extending to lateral malleolus Dm Operated Lt leg for varicosities : Herniorrhapy done 5 years back nil I/Cperforators at   B/L A/A,BK,AK ,B/L grade ISF junction incompetenceTC-8200,P60,L2,E8,12.1 ,2/8,RBS-172,UR-14,Cr-1.0
op no: 21888 70 M Farmer Pain 10 years Lt Multiple ulcer above Rt medial malleolus HT/DM SMOKER yes Lt-SFVJ incompetence  GRADE I TC-6800,DC-P54,L-42 ,E-4,HB-12.8,2/8/RBS-98,UR18,CR-0.8
op no;765/2015 52 M Tailor Pain/discharge 7 years Rt Rt-medial malleolus  above Operatedfor VARICOSE VEINS  4 years Rt side SMOKER YES Rt-SF Junction incompetence gradeII TC-5400,DC-P-56,L-44,ESR 4/8,HB-12.2,RBS-108,UR-20,CR-0.6
op no: 19002/12 61 M Worker in a shop PAIN 5years Rt Above medial malleolus multiple DM/HT NIL Rt-SF Junction incompetence gradeII TC-7800,DC-P-70,L-30,HB-12.1,ESR 2/8,RBS-108,UR-20,CR-0.6
OPNO:128675 60 M FIRE OFFICER pain 2months Lt Lt- back of medial malleolus Alcoholic/SMOKER YES LT-AA,AK,BK,PERFORTORSI/C TC-6200,DC-P-70,L30,HB-13.1 ESR-8/16,F-108,PP-120,UR-20,CR-0.6
op no: 78459 34 M Supervisor at Uds pain/Discharge 3 months Lt multiple ulcer above medial malleolus yes B/L multiple perfortar incompetence TC-5800,DC-P-72,L28,HB-12.2, ESR 4/8,RBS-98,UR-26, CR-0.6
OP NO79856 67 M Watchman pain 8 years Rt Rt- above medial malleolus DVT 2 years back,Known case of RHD ,MS,MR Alcoholic/smoker yes Rt- Recalcitrant DVT TC-6200,DC-P-60,L-32,E-8,HB-12.2, ESR 4/8,RBS-108,UR-27, CR-0.9
op no :1588 67 M cook pain/Discharge 20 years Lt Lt- above lateral malleolus yes Lt-SFV junction incompetence grade I BK<AK AA perforation I/C TC-7200,DC-P-72,L-28,HB-10.2, ESR 4/8,RBS-108,UR-26, CR-0.6
op no;35789 70 F watchman pain/Discharge 15 years Rt Rt- above medial malleolus OBESE yes Rt- SF junction incompetence grade II TC-5400,DC-P-68,L-26,E-6,HB-6.8,ESR-20/40,RBS-83,UR-20, CR-0.8
op no :131589 74 M ironman pain/Discharge 20 years Rt Rt- above medial malleolus Dm Alcoholic/smoker yes Rt-SFV junction incompetence grade I TC-7800,DC-P-62,L-36,E-2,RBS 80,UR-20,CR-0.9
op no :67586 65 M cook PAIN 5 YEARS Rt Rt- above medial malleolus yes Rt-sfV junction incompetence grade I,AK,BK,PERFORATOR INCOMPETENCETC-6800,DC-P 70,L-30,HB-12.2,ESR8/20
op no:4016 48 M securityofficer Pain 15 years Rt Rt- above medial malleolus OBESE Alcoholic yes Rt- BK,AA,AK PERFORATOR INCOMPETENCE  RT- SFV JUNCTION  INCOMPETENCE GRADE IITC-6800,DC-P 61,L-37, -2 HB-10.9,ESR 8/16
OP NO: 24675 67 M Farmer Pain/discharge 25YEARS Lt Lt-above medial Malleolus SMOKER YES Lt-SFV junction incompetence grade II TC-6200,DC-P-60,L-36,E-3,HB-11.2, ESR 4/8,RBS-98,UR-20 CR-0.9
op no:1996 46 M Coolie pain 15 years Rt Rt-above medial malleolus CRF/DM YES B/L-AA,BK,MID THIGH CALF PERFORATORS I/C TC-6200,DC-P-70,L30,HB-8.2, ESR-20/40,F-228,PP-308,UR-43,CR-1.6
op no: 42899 80 M Ironman discharge 10 years Rt Rt-above medial malleolus yes Rt-SF Junction incompetence gradeII,AA,BK,I/C TC-7800,DC-P-56,L-44,HB-12.2,ESR-2/8,RBS-98,UR-22,CR-0.6
DGS Aerobic-1 AEROBIC BACTERIA -2 ANAEROBIC BACTERIA  COLONY COUNT-1 COLONY COUNT-2PE ERY AK CIP COTRI CX PT GM CAZ CTX TETRA IMP VANCO CLINDA HLG
NO PUS CELLS ,few gpc in clusters Staphylococcus aureus (MSSA) NIL NIL 2.4 x104 S S S S S S S S S S
NO PUS CELLS ,NO ORGANISM Staphylococcus aureus (MSSA) 2.4 x 102 S S S S S S S S S S
Many pus cells,No organism Staphylococcus aureus (MRSA) NIL NIL 2.5 x 106 R R S R R R S R S S
Few pus cells ,Many GNB seen Proteus mirabilis , Enterococcus faecalis 6.8 X106, 9X105 NT/S NT/S S/NT S/S S/NT S/NT S/NT S/NT S S S/NT S/NT NT/S NT/S
Few pus cells ,few GNB seen Staphylococcus aureus (MSSA), Pseudomonas aeruginosa 1.9 x107 5.6x105 S/NT S/NT S/R S/R S/NT S/S NT/S S/R NT/S NT S/NT NT/S S/NT S/NT
few pus cells ,No organism Proteus mirabilis Peptostreptococcus anaerobicus 3.6 X104 NT NT S S S S S S S S S
NO PUS CELLS ,FEW GPB SEEN Diphtheriods 8.5X104 S NT NT S NT NT NT NT S
FEW EPITHELIAL CELLS,NO PUS CELLS Proteus mirabilis 4.2 x105 NT NT S R R S S S S S S S
FEW EPITHELIAL CELLS,many GNB SEEN Proteus mirabilis BACTIRIODIESFRAGILIS 1.2 x 107 NT NT S S S S S S S S R S
FEW PUS CELLS; NO ORGANISM NO GROWTH
FEW PUS CELLS ,NO ORGANISM Staphylococcus aureus (MRSA) 3.4 X106 R R S S R R S S S S
NO PUS CELLS NO ORGANISM Acinetobacter baumanii Peptostreptococcus anaerobicus 1.2X 104 NT NT S S S S S S S S S S
FEW PUS CELLS ,FEW GNB SEEN, Proteus mirabilis ;  Enterococcus faecalis Peptostreptococcus anaerobicus 5.3x 104 1.4x 106 NT/S NT/S S/NT S/S S/NT S/NT S/NT S/NT S/NT S/NT S/NT S/NT NT/S NT/S
FEW PUS CELLS,many GNB SEEN Pseudomonas aeruginosa Escherichia coli Peptostreptococcus anaerobicus 1.1x106 2.5 x104 NT NT S/S S/R NT/S S/S S/S S/S S/S NT/S NT/R S/S
NO PUS CELLS ,NO ORGANISM Proteus mirabilis Peptostreptococcus anaerobicus 8.4X104 2.4 x103 NT NT S S S S S S S S R S NT
No Pus cells;FewGPC in clusters,FewGNB seen Staphylococcus aureus (MSSA) Escherichia coli (ESBL) 2.7 x107 4.4 X 106 S/NT S/NT S/S S/S S/S S/S NT/S S/S NT/R NT/R S/S NT/S S/NT S/NT
FEW PUS CELLS ,NO ORGANISM S.epidermidis Peptostreptococcus anaerobicus 1.2X 104 S S R S S S S S S S
NO PUS CELLS ,GPCS IN CLUSTER SEEN S.epidermidis 3.5 X107 S S S R R S S S S S
NO PUS CELLS ,ManyGNB seen Proteus mirabilis ; Micrococci 7.2 x 106; 1.2X102 NT NT S S R S S R S S R S
NO PUS CELLS ,many  GPCS IN CLUSTER SEEN Staphylococcus aureus (MRSA) 5 X 106 R R S R S R S S S
NO PUS CELLS NO ORGANISM NO GROWTH
NO PUS CELLS NO ORGANISM Micrococci
NO PUS CELLS NO ORGANISM Staphylococcus aureus (MSSA) 2 X102 S R S R S S NT S NT NT S NT S S
NO PUS CELLS ,Few GNB seen Proteus mirabilis 3.4 X104 NT NT S R S S S S S S S S
NO PUS CELLS NO ORGANISM NO GROWTH
OCC Epithelial cells, No Pus Cells, No Organisms Escherichia coli (ESBL) Micrococci 1.6X 107 2 X102 NT NT S S S S S S R R S S
NO PUS CELLS ,NO ORGANISM Staphylococcus aureus (MSSA) 8.4 X103 S S S S S S S S S S
NO PUS CELLS Few GPC in chains GAS 3.4 X 104 S S S S S S S
NO PUS CELLS ,MANY GPCS IN CLUSTER:MANY GNB SEEN Pseudomonas aeruginosa; Staphylococcus aureus (MSSA) 5.9x104 1.1x105 NT/S NT/S S/S S/S NT/S S/S S/NT S/S S/NT NT NT/S S/NT NT/S NT/S
NO PUS CELLS NO ORGANISM Escherichia coli (ESBL) 3X 107 NT NT S S R S S S R R S S
few pus cells ,few gnb seen Klebsiella pneumoniae 4.2 x103 NT NT S S S S S S S S S S
NO PUS CELLS ,NO ORGANISM Staphylococcus aureus (MRSA) 3.2 X 107 R R S S R R NT R NT NT S S S
NO PUS CELLS ,Few GNB seen Pseudomonas aeruginosa; 1.25 X106 NT NT S S NT S S S S NT NT S
NO PUS CELLS ,NO ORGANISM S.epidermidis 3.4 X104 S S S R S S S S S S S
NO PUS CELLS ;MANY GNB SEEN Pseudomonas aeruginosa; Diphtheriods 3.6 X 105 2 X102 NT/S NT S/NT S/S NT S/NT S/NT S/NT S/NT NT NT S/NT NT/S
NO PUS CELLS ,NO ORGANISM Pseudomonas aeruginosa; 1.4x102 NT NT R R NT S S R S NT NT S
NO PUS CELLS,MANY GPB SEEN Pseudomonas aeruginosa; 3.4 X107 NT NT S S NT S S R S NT NT S
NO PUS CELLS ,NO ORGANISM Staphylococcus aureus (MSSA) 5.2 X102 S S S S R S R S S S
NO PUS CELLS,NO ORGANISM Staphylococcus aureus (MSSA) 1.2 X102 S S S R S S R R S S
NO PUS CELLS ,NO ORGANISM Micrococci 1.4 x102
FEW PUS CELLS,NO ORGANISM Staphylococcus aureus (MSSA) Diphtheriods 6.2 X104 3.4X 102 S/S S/NT S/NT S/S S/NT S/NT S/NT S/NT S/S
FEW PUS CELLS, FEW GNB SEEN Pseudomonas aeruginosa; 1.25 X105 NT NT S S NT S S R S NT NT S
NO pus cells; Occ GNB seen Klebsiella oxytoca 5.4 x104 NT NT R S S S S R S S R S
NO PUS CELLS,Many GPC in clusters Staphylococcus aureus (MRSA) 3.27 X107 R R S S R R NT S NT NT S S S
NO PUS CELLS,NO ORGANISM Enterococcus faecalis 2.4 x103 S S NT S NT NT NT NT NT NT NT NT S S
NOPUS CELLS ,NO ORGANISM NO GROWTH
NO PUS CELLS ,NO ORGANISM Proteus vulgaris 1.2 X102 NT NT S S S S S S S S S S
NO PUS CELLS ,NO ORGANISM Pseudomonas aeruginosa; 3.2X105 NT NT S S NT S S S S NT NT S
FEW PUSCELLS ,FEW GPC IN CLUSTERS Staphylococcus aureus (MSSA) GAS 4.2 X102 2.3 X102 S/S S/S S/NT S/S S/NT S/NT S/NT NT/S S/S S/S S/S
FEW GPC IN CLUSTERS SEEN,FEW PUS CELLS S.epidermidis 5.2 X105 S S S R R S R S S S
Few Pus cells ,few GNB seen Pseudomonas aeruginosa ; diphtheriods 6.6 x 103 1.4 X 104 NT/S NT R/NT S/S NT S/NT S/NT R/NT S/NT NT NT S/NT NT/S
NO PUS CELLS NO ORGANISM Klebsiella oxytoca Enterococcus faecalis 3 x 104 1.2 x103 NT/S NT/R S/NT S/S S/NT S/NT S/NT S/NT S/NT S/NT S/NT S/NT NT/S S
NO PUS CELLS ,ManyGPC in clusters Proteus vulgaris Staphylococcus aureus(MSSA) 1.2X103 3.4 X 105 NT/S NT/S S/R R/R R/S S/S S/NT S/R S/NT S/NT S/S S/NT NT/S NT/S
NO PUS CELLS ,Many GNB seen Pseudomonas aeruginosa Escherichia coli (ESBL) 1.4 X 105 3.5 X106 NT NT S/S S/S NT/S S/S S/S S/S S/R NT/R NT/S S/S
Few Pus cells ,No organism Staphylococcus aureus(MSSA) Klebsiella oxytoca 5.4 x 105 1.2 x103 S/NT R/NT S/S R/S R/S S/S NT/S S/S NT/S NT/S R/S NT/S S/NT S/NT
FEW PUS CELLS ,MANY GNB MANY GPC IN PAIRS SEEN Proteus vulgaris Peptostreptococcus anaerobicus 4.6 X104 NT NT S S S S S R S S R S
FEW PUS CELLS ,FEW GNB seen, FEW GPC IN PAIRS Pseudomonas aeruginosa, Staphylococcus aureus (MSSA) 1 x 106, 1.2 X 106 NT/S NT/S S/S R/R NT/R S/S S/NT S/S S/NT NT NT/S S/NT NT/S NT/S
NO PUS CELLS NO ORGANISM Staphylococcus aureus (MRSA) Diphtheriods 4.4 X 106 1.1 X 102 R/S R/NT S/NT S/S S/NT R/NT NT S/NT NT NT R/NT NT S/S S/NT
NO PUS CELLS FEW GNB SEEN Pseudomonas aeruginosa S.epidermidis 1.4 X 103 2.8 x103 NT/S NT/S R/S R/S NT/S S/S S/NT R/R S/NT NT NT/S S/NT NT/S NT/S
fewpuscells,few gnb seen Proteus vulgaris Escherichia coli 5.4 X 104 2.6 X103 NT NT S/S R/S S/R S/S S/S S/S S/S S/S S/S S/S
NO PUS CELLS,NO ORGANISM NO GROWTH
few pus cells ,No organism Escherichia coli S.epidermidis 3.2X104 5.4X105 NT/S NT/S S/S S/S R/R S/S S/NT R/S S/NT S/NT S/NT S/NT NT/S NT/S
NO PUS CELL, NO ORGANISM Staphylococcus aureus (MSSA) 2.9 X 102 S S R R S S R S S S
NO PUS CELL, NO ORGANISM Staphylococcus aureus (MSSA) 1.3 X104 S S S S S S S S S S
NO PUS CELL, FEW GNB SEEN Klebsiella pneumonia ; Peptostreptococcus anaerobicus 5.2X 105 NT NT R R S S S R S S S S
NO PUS CELL, many GNB seen Escherichia coli (ESBL) 3.4 X106 NT NT R S R S S R R R R S
FEW PUS CELLS ,few GPCS IN CLUSTERS seen Staphylococcus aureus (MRSA) 4.2 X106 R S S R R R S S S S
FEW PUS CELLS ,NO ORGANISM NO GROWTH
NO PUS CELL, NO ORGANISM Proteus mirabilis Micrococci 1.7 X 102 2.6 X103 NT NT R S R S S R S S S S
FEW PUS CELLS,NO ORGANISM Escherichia coli Staphylococcus aureus(MSSA) 3.4 X103 1.1 X 102 NT/S NT/S S/S S/R S/S S/S R/NT S/S S/NT S/NT S/S S S/S NT/S
FEW PUS CELLS, FEW GNB SEEN Proteus mirabilis Staphylococcus aureus (MSSA) 1.6 X103 5.3 X103 NT/S NT/S S/S S/R S/R S/S S/NT S/S S/NT S/NT S/S S/NT NT/S NT/S
NO PUS CELLS,NO ORGANISM klebsiella Oxytoca ESBL 3.5 X 106 NT NT S R R S R S R R S S
op no:83096 65 M cook Pain/discharge 15 years Rt Rt-above medial malleolus,extending into dorsum Alcoholic NIL Rt-SF Junction incompetence gradeII, TC-5400,DC-P45,L-50,E-4,M-1
op no:9384/15 52 M watchman pain 8 years Rt Rt-above medial malleolus Alcoholic/smoker Rt-dilated tortous veinRt-SF Junction incompetence gradeII,AA,BK,I/C TC-5800,DC-P-62,L-6,E-2,HB-15.2 ESR 4/8,RBS-120,UR-20,CR-0.6
op no:48037 37 M cook Pain/discharge 3 years Lt Lt-above medial Malleolus OBESE ALCOHOLIC/SMOKER B/L Varicoseveins B/L LL WITH MULTIPLE I/C PERFORATORS GRADE II SF JUNC I/C TC-4100,DC-P-50,L-42,E-8,HB-14.1,ESR-6/12,RBS-118,UR-19,CR-0.8
OPNO 49800 80 M Watchman Foul smell/discharge18  years Lt Lt-above medial malleolus Alcoholic/Smoker YES Lt-PARTIAL DVT TC-5800,DC-P-62,L-30,E-8HB-10.8,ESR-66,RBS-118,UR-20,CR-0.6
op no;445/09 72 M Farmer Pain 3 years Rt Rt-above medial malleolus YES Rt-BK,Mid calf Perforators I/C TC-5400,DC-P-54,L-46,HB-12.8,ESR 2/8,RBS-98,UR-20,CR-0.6
OP NO:185/08 38 M Saloon shop worker Increased pain and discharge10 ye rs Rt Rt-above medial malleolus Skin grafting done 3 years back NIL NIL Rt-GSV dilated and torsurous, Below knee perforator and Slow flow inGSV and partial thrombosisTC-8400,DC-P60,L32,E7,HB-11.9,ESR-10/35,RBS-95,UREA-30,CR-1.1
OP NO:2071/14 78 M watchman discharge 7 YEARS Lt Lt-above lateral Malleolus Operated for 4 years for varicose veins ALCOHOLIC/SMOKER NIL Lt-SFV Junction incompetence grade -I,Multiple perforators IncompetenceTC-5400,DC-P-68,L-26,E-6,HB-7.9,ESR-20/40,RBS-83,UR-20, CR-0.8
OP NO: 05961 39 F FARMER discharge 5 years Lt Lt- above medial malleolus obese yes B/E SFV JUNCTION INCOMPETENCE GRADE-1 B/L BK,AA with lateral medial calf perforator incompetenceTC-5800,DC-P62,L30,E8,HB-7.7,ESR-66,RBS-83,UREA-21,CR-0.6
OPNO186956 23 M Leather factory supervisor discharge 1 year lt Lt- above medial malleolus NIL NIL Lt-Femoral DVT with B/K perforator incompetence,GSV -NORMALTC-6800,DC-P78,L15,E7,RBS-65,UREA-23,CR-1.0ESR-20,HB-10.5
op no:138219 72 M TEA MASTER Pain 20 YEARS Rt Rt-above medial malleolus inguinal hernia operated -13 years backGSV strapping don  -5ye rs back ALCOHOLIC/SMOKER NIL B/L BK,AK,PERFORATOR INCOMPETENCE TC-5200,P56,L-34,M-2,HB-15.2,ESR 2/8 ,RBS-94,UR-24,CR-0.8
OP NO 192456 28 M Tiles worker pain  3years Rt Rt-above medial malleolus obese OPERATED FOR VARICOSE VEINS - 3YEARS SMOKER yes B/L PERFORATOR INCOMPETENCE TC-4800,DC-P-64,L32,E4 HB-15.2,ESR -8/16,RBS-98,UR-22,CR-0.8
IP NO 56648 60 M UNEMPLOYED PAIN AND FEVER 10 years LT Lt-lateral malleolus ALCOHOLIC YES LT-ILEOFEMORAL DVT TC-15800,DC-P94,L3,M3,HB-8.2 RBS-128,UREA-40,CR-2.5
OP NO 190141 32 M Security worker discharge 3YEARS RT Rt-above medial malleolus NIL YES RT-Grossly dilated torturous vein found in thigh and leg AA incompetence TC-5400,DC-P72,L-28,HB-12.2,ESR 2/8,RBS-108,UR-26,CR-0.6
OP NO 44644 47 M Tea stall worker Pus/discharge/Maggots2 years Rt Rt-above medial malleolus NIL YES Grade II SF Junction Incompetence with R AA perforator R lateral medial calf perforator IncompetenceTC-7000,DC-P80,L15,E,ESR24/HR MM,HB 16.8 RBS 66 UREA 4,CR-1.5
op no4932/12 70 M retired pwd worker swelling 15 years Rt Rt-above medial malleolus DM ALCOHOLIC YES B/L R- SF Junction grade-II, L-Grade-I B/L Mid calf perforator IncompetenceTC-10200,DC-P-70,L-28,E-2,HB-14.2,ESR-2/8,RBS 98,UR-26,CR-1.0
OP NO 1224/2015 49 M Farmer swelling/pain 2 yeasr Rt Rt-above medial malleolus NIL YES Rt-Cfv -recanalised vein,Dilated Femoro popliteal vein SF Junction grade I I/C Thrombosis superficial vein on R calfTC-6000,D -P47,L40,E-10,M-3,HB-12.5,UREA-22, CR-1.1
OP NO 1762/14 65 M TAILOR discharge 3 years Lt Lt- above medial malleolus DM/ CABG -5 YEARSBACK NIL YES Lt-SFV Junction incompetence grade -I TC-8000,DC P70,L0,HB-10.2 ESR-8/16,R 98, UR-, CR-0.9
OP NO 1689/15 50 F TAILOR PAIN 2 YEARS RT RT-lateral malleolus OPERATED FOR  IVC THROMBOSIS -5 YEARS BACK ON ANTICOAGULANTSNIL YES B/L GSV grade I Incompetence, Perforator incompetence B/L BK,AA, PerforatorsTC-9300,DC-P058,L34,E8,HB-9.8,RBS-120,UEA-24,CR-1.2
OP NO 773/10 57 M COOK pain and discharge 15 years Lt Lt- above medial malleolus YES Lt SFJI/C;AA PERFORATOR I/C TC-8700,DCP73,L22,E5,HB-10.9,RBS-66,UREA-18,CR-1,1
OP NO 1965/15 27 M Sales representative Pain  3years Rt Rt-above medial malleolus yes Rt-recanalised GSV (Dilated) Fibrosis extending from ankle to SFV TC-4100,DC-P-50,L-42,E-8,HB-14.1,ESR-6/12,RBS-118,UR-19,CR-0.8
OP NO 19265 60 F COOK pain /discharge 10 years Rt RT-above medial malleolus DM yes B/L SFV JUNCTION INCOMPETENCE TC-5800,DC-P-62,L-30,E-8HB-10.8,ESR-66,RBS-118,UR-20,CR-0.6
OP NO 1076/12 40 M XEROX SHOP OWNER PAIN 6 YEARS RT RT-lateral malleolus-MULTIPLE OBESE SSG -6 YEARS NIL NIL RT-AA PERFORATOR INCOMPETENCE TC-7600,DC-P76,L24
OP NO 1267/15 56 M watchman discharge 20 years LT LT- lateral malleolus YES LT-AA,PERFORTORSI/C TC-5200,DC-P72,L26,E2,HB-15.2,UREA-15,CR-0.7
OP NO 1489/15 63 F Tailor discharge 15 YEARS LT Lt-Above medial Malleolus DM YES LT-Partially recanalised popliteal vein TC-6900,DC-P73,L-26,E-1, HB 8.8,UREA-20,CR-1.1
OP NO6725 52 M watchman discharge 8 YEARS LT Lt-Above medial Malleolus KNOWN CASE OF RHD -MVR _12 years B/L VARICOSE VEINS-10 YEARS YES Lt-SFV Junction incompetence grade -I,AA I/C TC-68,HB-12.2 ,DC-P 47,L42,E 11,UREA-23,CR-0.8
OP NO 7269/14 44 M TAILOR PAIN 5 YEARS RT Rt-above medial malleolus ALCOHOLIC YES Rt- SF junction incompetence grade II TC-5600,DC-P-70,L-0,HB-15.0GMS,ESR2/8,RBS-128 UREA-30,CREATININE0.8
OP NO 246/09 55 M UN EMPLOYED DISCHARGE 1O YEARS LT Lt- above medial malleolus ALCOHOLIC YES Lt-SFV Junction incompetence grade -I TC-8300,DC-P82,L16,E2
IP NO 15472 67 M WATCHMAN DISCHARGE 5 YEARS LT LT-MULTIPLE ULCERS OVER THE lateral malleolus DM/HT SMOKER YES Lt-SFV Junction incompetence grade -I,Multiple perforators IncompetenceTC-5400,DC-P56,L36,E8,RBS-108,UREA-22,CR-1.1
GPC IN PAIRS AND SHORT CHAINS, NO PUS CELLS Staphylococcus aureus (MRSA) Enterococcus faecalis 4.6 X 106 1.3 X 103 R/S S/R S/NT S/S R/NT R/NT NT S/NT NT NT S/NT NT S/S NT/S
NO PUS CELLS ,NO ORGANISM Staphylococcus aureus (MSSA) Acinetobacter baumanii 2.6 X103 2.4 X104 S/NT R/NT S/S S/S S/S S/S NT/S S/S NT/S NT/S S/S NT/S S/NT
Few Pus CELLS, many GNB seen Escherichia coli Micrococci 1.2 X107 4.3 X102 NT NT R R S S S R S S S S
NO PUS CELLS,NO ORGANISM Proteus vulgaris S.epidermidis 5.4X 105 2.8 x103 NT/S NT/S S/R S/S S/S S/S S/NT S/R S/NT S/NT S/R S NT/S NT/S
NO PUS CELLS,Many GNB seen ,Few GPC in clusters seen Staphylococcus aureus (MSSA) Pseudomonas aeruginosa 4.3 X104 2.7 X105 S/NT S/NT S/S R/R R/NT S/S NT/S S/R NT/S NT S/NT NT/S S/NT S/NT
NO PUS CELLS ,NO ORGANISM Enterococcus faecalis 5.2 X104 S R NT S NT NT NT NT NT NT NT NT S NT S
few pus cells and few gnb seen Escherichia coli Peptostreptococcus anaerobicus 4.6 X102 NT NT S S R S S R S S S S
NO PUS CELLS,MANY GPB SEEN DIPHTHERIODS 2.4 X 103 S NT NT S NT NT NT NT S
Many Pus cell seen,Many GPC in clusters Staphylococcus aureus (MSSA) 3.8 X107 S R R R R S R R S S
NO PUS CELLS NO ORGANISM NO GROWTH
NO PUS CELLS ,FEW GPC IN CLUSTERS  Staphylococcus aureus (MRSA) 4. 3 X106 R S S S R R NT S NT NT S S S
Many pus cells,MANY GNB SEEN Escherichia coli (ESBL) S.epidermidis Peptostreptococcus anaerobicus 5.3 x106 2.4 x104 NT/S NT/S S/S S/S R/S S/S S/NT S/S R/NT R/NT S/S S NT/S NT/S
Occ pus cells ,Many GPC in clusters  Staphylococcus aureus (MRSA) 1.24 x107 R R R R R R NT R NT NT R S S
Many pus cells,MANY GNB SEEN Escherichia coli Enterococcus faecium 2.5 x 107 3.1 x 102 NT/S NT/S S/NT S/R S/NT S/NT S/NT S/NT S/NT S/NT S/NT S/NT NT/S NT/S
Many pus cells,MANY GNB SEEN Pseudomonas aeruginosa Staphylococcus aureus (MSSA) 4.3 x106 2.3 x105 NT/S NT/S S/S S/S NT/S S/S S/NT S/S S/NT NT NT/S S/NT NT/S NT/S
NO PUS CELL FEW GPCS IN CLUSTERS SEEN  Staphylococcus aureus (MRSA) 3.2 X 107 R S S S S R S S S S
FEW PUS CELLS,FEW GNB SEEN, FEW GPC IN PAIRS SEEN Klebsiella pneumoniae Peptostreptococcus anaerobicus 4.3x 104 NT NT R S S S S R S S S S S
FEW PUS CELLS, NO ORGANISM Escherichia coli Enterococcus faecalis 5.4 x 104 3.1 x 104 NT/S NT/S S/NT S/S S/NT S/NT S/NT S/NT S/NT S/NT S/NT S/NT NT/S NT/S
NO PUS CELL ;NO ORGANISM NO GROWTH
no pus cells;FEW GPCS IN CHAINS AND PAIRS GAS 5.2 X104 S S NT S S NT NT NT S S S S
no pus cells ;no organism  Staphylococcus aureus (MRSA) 2.6 X106 R R R R R R NT R NT NT R S S
no pus cells ;no organism s.epidermidis BACTIRIODIESFRAGILIS 3.5 x 104 S S S S S S S S S S
few pus cells ,few GPCS IN CLUSTERS seen Staphylococcus aureus (MSSA) 1.2 X 102 S S S S S S R S S
FEW PUS CELLS;MANY GNB SEEN Klebsiella oxytoca Peptostreptococcus anaerobicus 1.3x 106 NT NT R R R S S R S S R S
NO PUS CELLS FEW GPC IN CLUSTERS  Staphylococcus aureus (MRSA) 4.5 X 106 R R R S R R R R S S
no pus cells ;no organism Staphylococcus aureus (MSSA) 2.6 X103 S S S R R S S S S S
NO PUS CELLS NO ORGANISM NO GROWTH
FEW PUS CELLS SEEN;FEW GNB SEEN Proteus vulgaris Enterococcus faecalis 4.3 x106 5.5 x 106 NT/S NT/S S/NT S/S S/NT S/NT S/NT S/NT S/NT S/NT S/NT S/NT NT/S NT/S
KEY TO MASTER CHART
M-Male,F-Female,DM-Diabetes mellitus,HT-Hypertension,TC-Total count,DC-Differential count ,OP-outpatient,IP-Inpatient
 R-Resistant, S-Sensitive NT- Not tested
** Sensitivity to Diphtheroids were interpreted according to British Society ofAntimicrobial Chemotherapy guidelines. 
*Clindamycin sensitivity was reported after testing with Inducible D test according to    the CLSI guidelines.
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